SUBJECT INDEX: VOLUME 39(1999)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 39 (1999), Number One (January) contains pages 1–119; Number Two (February), pages 120–228; Number Three (March), pages 229–340; Number Four (April), pages 341–438; Number Five (May), pages 439–548; Number Six (June), pages 549–664; Number Seven (July), pages 665–794; Number Eight (August), pages 795–916; Number Nine (September), pages 917–1036; Number Ten (October), pages 1037–1154; Number Eleven/Twelve (November/December), pages 1155–1306.

A
A blood group, agglutination index, ... 1051
ABH system antigen, *Aplysia* gonad lectin, ... 1060
ABO, ... 1155(E)
ABO chimera
  hematopoietic colony-derived DNA, ... 1247
  immunohematology, ... 1247
ABO grouping
  gel agglutination assay, ... 300
  immunohematology, ... 300
ABO incompatibility
  allogeneic bone marrow transplantation, ... 179
    acute myelogenous leukemia, ... 179
    erythroid aplasia, ... 179
    hemolysis, ... 179
    multiple-organ failure, ... 179
    myelodysplastic syndrome, ... 179
    sepsis, ... 179
  bone marrow transplantation
    major ABO incompatibility, ... 1273(L)
    minor ABO incompatibility, ... 1273(L)
  pregnancy
    direct antiglobulin test, ... 26
    solid-phase screening test, ... 26
ABO mosaicism
  genomic analysis, ... 1247
  hematopoietic colony-derived DNA, ... 1247
  immunohematology, ... 1247
Acetylcholine receptor
  albumin, ... 682
  EXCORIM, ... 682
  immunoadsorption system, ... 682
  plasma exchange, ... 682
  staphylococcal protein A immunoadsorption system, ... 682
Acid phosphatase, ... 410
Acquired B antigen, ... 543(L)
Acquired coagulation factor deficiency, activated partial thromboplastin time, ... 56
  sensitivity of tests compared, ... 56
Activated factor VII, citrate, ... 1266
Activated glycoprotein IIb/IIIa
  cryopreserved platelet, ... 880
  fresh platelet, ... 880
  liquid-preserved platelet, ... 880
Activated hemostasis, citrate, ... 1266
Activated partial thromboplastin time
  acquired coagulation factor deficiency, ... 56
    sensitivity of tests compared, ... 56
  dilutional coagulopathy, tests compared, ... 56
  surgical bleeding, ... 56
    sensitivity of tests compared, ... 56
Activation marker expression, white cell reduction, ... 724
Acute hepatitis, ... 522
Acute lymphoblastic leukemia
  anti-c, ... 763
  anti-E, ... 763
  antigen matching, ... 763
  anti-K, ... 763
  GB virus type C, ... 212
    alanine aminotransferase, ... 212
    anti-E2, ... 212
  Rh system antibody, ... 763
Acute myelogenous leukemia, ... 179, 824
  anti-c, ... 763
  anti-E, ... 763
  antigen matching, ... 763
  anti-K, ... 763
  CD34+ cell, ... 442
  pooled random-donor platelet, ... 925
  Rh system antibody, ... 763
  single-donor platelet, ... 925
Acute normovolemic hemodilution, ... 910
  blood loss, ... 396
  blood volume, ... 396
  hematocrit, ... 396
  mathematical modeling, ... 396
Acute renal failure, albumin, diluted with sterile water, ... 110(L)
Acute retroviral syndrome
  anti-human immunodeficiency virus enzyme immunoassay, .. 383
  blood donor, ... 383
  CD4+, ... 383
  human immunodeficiency virus p24 antigen assay, ... 383
  human immunodeficiency virus polymerase chain reaction, ... 383
  immunosilent AIDS, distinguishing, ... 383
  Western blot, ... 383
Adenosine deaminase, ... 343
Administration
  autologous transfusion cost-effectiveness, ... 808
  blood component recall, ... 473
  cord blood cost, ... 645
  Investigational New Drug license, ... 357
  limited-donor program, ... 938
  phlebotomy for hemochromatosis, ... 651
  recombinant human erythropoietin, ... 933
  record errors, ... 351
  single-donor platelet, ... 925
  virus-inactivated plasma cost-effectiveness, ... 479
Adsol blood preservative, ... 565
  hemorrhage, massive resuscitation, ... 998
  swine model, ... 998
  transfusion practice, ... 998
Adult T-cell lymphoma, ... 1104
Affinity-adherence test system
  antibody reactivity, ... 1045
  anti-Le^a antibody, ... 1045
  anti-Le^b antibody, ... 1045
  anti-M antibody, ... 1045
  anti-N antibody, ... 1045
  anti-P_1 antibody, ... 1045
  tube low-ionic-strength solution indirect antiglobulin test, compared, ... 1045
African, CD36 deficiency
  frequency, ... 873
  platelet immunization, ... 873
Age, blood donor, ... 316
Agglutinating antibody, optical density, ... 1051
Agglutination, Fab fragment, ... 364
Agglutination index
  B blood group, ... 1051
  A blood group, ... 1051
  blood group, ... 1051
  blood type, ... 1051
  D blood type, ... 1051
  immunohematology, ... 1051

O blood group, ... 1051
ultraviolet and visible light spectrophotometry, ... 1051
AIDS. *See also* Immunosilent AIDS
anti-human immunodeficiency virus enzyme immunoassay, .. 383
CD4+, ... 383
human immunodeficiency virus p24 antigen assay, ... 383
human immunodeficiency virus polymerase chain reaction, ... 383
Western blot, ... 383
Ala_{354} D epitope, ... 17
Alanine aminotransferase, ... 188, 194
hemochromatosis proband, ... 578
non-A to -G hepatitis, ... 522
Albumin, ... 120(E)
acetylcholine receptor, ... 682
acute renal failure, diluted with sterile water, ... 110(L)
AmpliScreen Hepatitis C (HCV) Test, ... 1111
autoimmune disorder, ... 682
hemolysis, diluted with sterile water, ... 110(L)
hepatitis B virus, ... 1160
hepatitis C virus, ... 1160
human immunodeficiency virus, ... 1160
IgG antibody, ... 682
myasthenia gravis, ... 682
virus transmission, ... 1160
Albumin and papain technique, antibody detection, ... 1097
Allergic transfusion reaction, white cell-poor platelet preparation, ... 1179
Alloantibody
detection in patients with autoantibodies, ... 6(E)
warm autoantibody
1-in-5 dilution approach, ... 11
detection methods compared, ... 11
dithiothreitol and enzyme reagent, ... 11
polyethylene glycol adsorption, ... 11
ZZAP adsorption, ... 11
Allogeneic blood transfusion
bacteremia, ... 694
bacterial infection, ... 694, 808
cost, ... 694
hip fracture, ... 694
buffy coat-depleted blood component, ... 625
immunomodulatory effects, ... 718
osteomyelitis, ... 694
pneumonia, ... 694
septic arthritis, ... 694
wound infection, ... 694
Allogeneic bone marrow transplantation, ... 1212
ABO incompatibility, ... 179
acute myelogenous leukemia, ... 179
erythroid aplasia, ... 179
hemolysis, ... 179
multiple-organ failure, ... 179
myelodysplastic syndrome, ... 179
sepsis, ... 179
Allogeneic buffy coat-depleted red cell, CD8+ cell, ... 1089
Allogeneic buffy coat-poor blood, immunologic changes, ... 1089
Allogeneic cord blood transplant, ... 357
Allogeneic peripheral blood progenitor cell transplantation
minor ABO incompatibility, delayed massive immune hemolysis, ... 824
transplantation, ... 824
Allogeneic red cell, CD3+ cell, ... 1089
Allogeneic white-cell reduced blood
immunologic changes, ... 1089
T-cell proliferation, ... 1089
Alloimmune thrombocytopenia, ... 372
Alloimmunization, ... 818
co-stimulation, ... 818
Alloimmunization to D, fetus
fetal hemolysis, ... 1235
immunoglobulin, ... 1235
outcome, ... 1235
pregnancy, ... 1235
Aluminum phthalocyanine tetrasulfonate
granulocyte, ... 599
lymphocyte, ... 599
monocyte, ... 599
white cell, ... 599
AMICUS cell separator, ... 572
CD41, ... 74
CD42b, ... 74
CD62p-positive platelet, ... 74
CD63-positive platelet, ... 74
coagulation, ... 420
D-dimer, ... 420
donor reactions, ... 895
fibrinogen binding, ... 74
fibrinolysis, ... 420
lymphocyte, ... 420
monocyte, ... 420
mononuclear cell, ... 420
neutrophil, ... 420
plasminogen activator inhibitor, ... 420
plasmin-plasmin inhibitor complex, ... 420
platelet, ... 895
platelet-neutrophil aggregate, ... 420
prothrombin fragment, ... 420
Spectra LRS separator, efficiency compared, ... 895
white cell reduction, ... 572, 895
Aminomethyltrimethyl psoralen
febrile nonhemolytic transfusion reaction, ... 239
interleukin ... 8, 239
AmpliScreen Hepatitis C (HCV) Test
albumin, ... 1111
analytical sensitivity, ... 1111
bilirubin, ... 1111
blood-borne viruses, ... 1111
hemoglobin, ... 1111
hepatitis B virus, ... 1111
hepatitis C virus, ... 1111
hepatitis C virus genotype, ... 1111
hepatitis C virus RNA, ... 1111
human immunodeficiency virus type ... 1, 1111
sample collection, ... 1111
sensitivity, ... 1111
triglyceride, ... 1111
Anemia, ... 1070
blood loss, ... 396
fetus, ... 149, 156
fetal hemolysis, ... 1235
immunoglobulin, ... 1235
outcome, ... 1235
pregnancy, ... 1235
hematocrit, ... 396
preoperative autologous blood donation, ... 174
preterm infant, ... 149, 156
red cell substitute, ... 396
two-unit red cell apheresis, ... 218
Animal model, hemorrhagic shock, ... 998
Annexin V
granulocyte, ... 599
lymphocyte, ... 599
monocyte, ... 599
white cell, ... 599
Anti-At^a
black patient, ... 834
hemolytic disease of newborn, ... 834
hemolytic transfusion reaction, ... 834
transfusion complication, ... 834
Antibody detection
albumin and papain technique, ... 1097
polyethylene glycol technique, ... 1097
transfusion complication, ... 1097
Antibody reactivity
polyethylene glycol, ... 1272(L)
storage, ... 1272(L)

Antibody screening test
37°C reading
immune hemolysis, 295
transfusion reaction, 295
temperature, 37°C agglutinins, 229(E)
Anti-c
acute lymphoblastic leukemia, 763
acute myeloid leukemia, 763
chronic lymphocytic leukemia, 763
muscular dystrophy, 763
myeloproliferative syndrome, 763
non-Hodgkin's lymphoma, 763
Anti-C, hemolytic disease of newborn, 531
Anti-CD36, 873
Anti-CD62a, 967
Anti-D, hemolytic disease of newborn, 531
Anti-E
acute lymphoblastic leukemia, 763
acute myeloid leukemia, 763
chronic lymphocytic leukemia, 763
muscular dystrophy, 763
myeloproliferative syndrome, 763
non-Hodgkin's lymphoma, 763
Anti-G
fetomaternal red cell incompatibility, 531
hemolytic disease of newborn, 531
pregnancy, 531
Antigen matching
acute lymphoblastic leukemia, 763
acute myeloid leukemia, 763
chronic lymphocytic leukemia, 763
muscular dystrophy, 763
myeloproliferative syndrome, 763
non-Hodgkin's lymphoma, 763
Antigen recognition, lectin, 1060
Antigen-negative cell, 163
Antigen-positive cell, 163
Antiglobulin technique, 1065
Antiglobulin test
immunoglobulin, 537(L)
polyethylene glycol, 537(L)
Anti-Go^a, hemolytic disease of newborn, 537(L)
Antihemophilic factor
hepatitis B virus, 1160
hepatitis C virus, 1160
human immunodeficiency virus type I, 1160
virus transmission, 1160
Anti-Hr_O
hemolytic disease of newborn, 1151
pregnancy, 1151
Anti-human immunodeficiency virus enzyme immunoassay
acute retroviral syndrome, 383
AIDS, 383
immunosilent AIDS, 383
Anti-I reagent, 1060
Anti-K
acute lymphoblastic leukemia, 763
acute myeloid leukemia, 763
chronic lymphocytic leukemia, 763
muscular dystrophy, 763
myeloproliferative syndrome, 763
non-Hodgkin's lymphoma, 763
Anti-NS5, 790(L)
Anti-Tc^a
complement-specific antiglobulin reagent, 948
differential typing, 948
direct antiglobulin test, 948
haptoglobin, 948
hemoglobin, 948
hemolytic transfusion reaction, 948
lactate dehydrogenase, 948
monocyte monolayer assay, 948
Tc(a+) red cell, 948
transfusion complication, 948
Antithrombin, citrate, 1266
Antithrombin III, fresh-frozen plasma, 488
Apheresis. *See also* Therapeutic apheresis
CD34+ cell
cell count predictive value, 442
maximizing yield, 442
filgrastim
adverse events, 555
apheresis-related adverse events, 555
bone pain, 555
CD34+ cell dose collected, 555
fatigue, 555
headache, 555
nausea, 555
preapheresis white cell count, 555
safety, 555
HLA sensitization, female donors, 103
platelet antigen, 742
white cell
cell count predictive value, 442
maximizing yield, 442
Apheresis component, volumetric capillary cytometry, 864
Apheresis device
combined collection, 565
peripheral blood progenitor cell, 1200
Apheresis platelet, 1027
continuous filtration, 74
filtration, 74
recombinant human megakaryocyte growth and development factor, 258
white cell reduction, 74
Apheresis yield, 1027
retrospective study, 1207
Aplysia gonad lectin
ABH system antigen, 1060
bovine spleen galectin, 1060
Erythrina corallodendron lectin, 1060
galactophilic lectin, 1060
human anti-I, 1060
I-negative adult red cell, 1060
I-positive adult red cell, 1060
O_h red cell, 1060
P system antigen, 1060
plant lectin, 1060
Pseudomonas aeruginosa (galactophilic) lectin, 1060
Sophora japonica lectin, 1060
temperature, 1060
Apoptosis induction
lymphocyte, 599
monocyte, 599
white cell, 599
Applied blood group serology, book review, 436
Arterial hypotension, 998
Arthroplasty, 1089
AS-1 red cell, gamma irradiation
hemolysis, 128
in vitro properties, 128
potassium, 128
red cell ATP, 128
storage time, 128
viability, 128
Asp_{350}, D epitope, 17
AS.TEC 204, 572
white cell reduction, 572
Autoantibody, detecting alloantibodies, 6(E)
Autoimmune disorder
albumin, 682
EXCORIM, 682
immunoadsorption system, 682
plasma exchange, 682
staphylococcal protein A immunoadsorption system, 682
Autologous blood donation, 1027

See also Preoperative autologous blood donation
bacterial infection, 808
buffy coat-depleted blood component, 625
buffy coat-poor blood, immunologic changes, 1089
conference report, 910
cost-effectiveness, 808
decreasing overcollection, 801
hemoglobin, 801
hysterectomy, 801
iatrogenic anemia, 801
iron
allogeneic blood transfusion, 465
elective surgery, 465
hemoglobin, 465
intravenous iron, 465
number of autologous units donated, 465
oral iron, 465
randomized controlled study, 465
red cell production, 465
recombinant human erythropoietin, 933
risks and benefits, 801
Autologous bone marrow transplant, IgA deficiency, 457
circulating anti-IgA, 457
cryopreserved autologous plateletpheresis components, 457
manually allogeneic plateletpheresis components, 457
washed red cells, 457
Autologous white-cell reduced blood
immunologic changes, 1089
T-cell proliferation, 1089
Automated apheresis system, CD34+ cell, 48
CD34+ cell collection efficiency, 48
cell composition, 48
patient platelet and red cell loss during leukapheresis, 48
platelet collection efficiency, 48
volume, 48
Automated collection system
packed red cell unit, 460
single-donor platelet component, 460
white cell-reduced platelet component, 460
Automated leukapheresis system
peripheral blood progenitor cell, 1200
transplantation, 1200
Automated plasmapheresis, citrate, prospective study, 1266
Automated plateletpheresis
blood collection, 899
hematopoietic growth factor
erythropoietin, 899
interleukin-1β, 899
interleukin-6, 899
stem cell factor, 899
systemic levels, 899
thrombopoietin, 899
Automated specific treponemal test, syphilis, 206
AutoPBSC, 48
AutoPBSC tubing set
CD34+ cell, 1200
collection efficiency, 1200
engraftment kinetics after transplantation, 1200
mature blood cells, 1200
platelets, 1200
CD34+ cell, 48
CD34+ cell collection efficiency, 48
cell composition, 48
patient platelet and red cell loss during leukapheresis, 48
platelet collection efficiency, 48
volume, 48
mononuclear cell procedure
CD34+ cell, 1200
collection efficiency, 1200
engraftment kinetics after transplantation, 1200
mature blood cells, 1200
platelets, 1200
Avidin, 149

B
B blood group, agglutination index, 1051
B isohemagglutinin
gel agglutination assay, 300
tube agglutination, 300
Baboon model, platelet, 880
Bacteremia, allogeneic blood transfusion, 694
Bacterial infection
allogeneic blood transfusion, 694
cost, 694
hip fracture, 694
allogeneic transfusion, 808
autologous transfusion, 808
dose-response relationship, 694
*bcrl abl*translocation
chronic myelogenous leukemia, 387
reverse-transcriptase polymerase chain reaction, 387
Bedside filtration
nonhemolytic transfusion reaction, 1179
white cell-poor platelet preparation, 1179
Bilirubin, AmpliScreen Hepatitis C (HCV) Test, 1111
Biologic response modifier
filtration, 498
gamma radiation, 498
storage, 498
Biotin
^{51}Cr, compared, 149
red cell, 149
measuring circulating red cell volume, 149
measuring red cell survival, 156
red cell antigen, 163
antigen-negative cells, 163
antigen-positive cell, 163
BIRMA-1 monoclonal anti-A, 163
Di(b+) red cell, 163
hemagglutination assay, 163
LW(a+) red cell, 163
MH04 monoclonal anti-A agglutinated red cell, 163
polyclonal anti-A, 163
Biotin-X-N-hydroxysuccinimide, 880
Biotinylation
platelet, nitric oxide, 506
red cell
antibodies, 1065
antiglobulin technique, 1065
circulating kinetics, 1065
dithiothreitol, 1065
group O red cell, 1065
IgG antibodies, 1065
immunogenicity, 1065
immunohematology, 1065
neoantigens, 1065
red cell volume, 1065
BIRMA-1 monoclonal anti-A, 163
Black patient, anti-At^a, 834
Blood: An Epic History of Medicine and Commerce, book review, 793
Blood collection
automated plateletpheresis, 899
bone-specific alkaline phosphatase, 410
cell separator comparison, 420, 572
citrate, 1266
filgrastim, 555
granulocyte–colony-stimulating factor timing, 561
hematopoietic growth factor, 899
human T-lymphotropic virus type I *tax* sequence, 904
kinetics of peripheral blood stem cell harvests, 403
new apheresis procedure, 565
nucleic acid amplification testing, 1141
osteocalcin, 410
plateletpheresis, 895
Blood component
24-hour whole-blood storage clotting factor effect, 488

AS-1 RCC, 128
autologous platelet preparation, 144
biotin-labeled red cell, 149, 156
Creutzfeldt-Jakob disease, 1169
cytokine, 271
cytokine elimination, 239
dimethyl sulfoxide, 70
factor VIII/von Willebrand factor complex, 748
filtration of apheresis platelets during collection, 74
granulocyte antibody, 983
hematopoietic progenitor cell, 70
hemoglobin, 226(L), 271
IgG anti-D, 515
IgG subclass concentration, 515
immune globulin, 249
lactate, 492
methylene blue, 748
methylene blue-treated plasma, 63
new generation, 1027
  evolution, 1027
  safety, 1027
nitric oxide, 506
peripheral blood lymphocyte, 343
platelet, 880
platelet activation, 616
platelet antigen, 742
platelet components, 735
platelet storage lesion, 258
psoralen, 239
RANTES, 498
recombinant human megakaryocyte growth and development factor with polyethylene glycol, 258
red cell, 991
red cell 2,3 DPG, 492
red cell photodynamic sterilization, 599
red cell storage, 277
second-messenger effector, 135
soluble vascular endothelial growth factor, 1078
storage, 616, 951, 991
temperature, 991
tissue factor, 975
tissue factor pathway inhibitor, 975
transforming growth factor-β, 498
transmissible spongiform encephalopathy, 1169
  high-speed centrifugation, 1169
  infectivity levels, 1169
  intracerebral route, 1169
  white cell-reduction filtration, 1169
tumor cell irradiation, 608
ultraviolet A light, 239
white cell filtering temperature, 265
white cell reduction, 718, 724
white cell-reduced apheresis platelet, 960
Blood component recall
Food and Drug Administration, 439(E), 473
  effectiveness, 440(E)
  elements, 440(E)
  philosophy and policy, 440(E)
  process, 440(E)
  reasons for notification, 440(E)
  recall authority, 439(E)
United States, 473
  frequency, 473
  hazard class, 473
  nature, 473
  recall reason, 473
Blood donor
acute retroviral syndrome, 383
allogeneic cord blood bank deferral rate, 415
altruistic intent, 1018
donor recruitment, 1128
donor return behavior, 1128
  age, 1128
  donation interval, 1128
  education level, 1128
  first-time donors, 1128
  frequency of donations, 1128
  Rh-negative donor, 1128
  timing of subsequent donations, 1128
donor-history screening, 473
elderly patient, preoperative autologous blood donation, 174
geographic screening question, 310
granulocyte–colony-stimulating factor, 1136
hemochromatosis proband, 578
HLA sensitization, 103
human T-cell lymphotropic virus type I, 1145
  screening efficacy, 1104
immunosilent AIDS, 383
iron, 465
Japan, screening, 1104
motivation for volunteer donor system, 1018
multiparous, 103
plasmapheresis program, reasons for cessation of participation, 900
syphilis, 206
Trypanosoma cruzi
  congenital transmission, 310
  seroprevalence, 310
unstable angina, 542(L)
vasovagal reaction, 316
  age, 316
  blood pressure, 316
  donation status, 316
  pulse, 316
  sex, 316
  weight, 316
voluntary, Food and Drug Administration regulations, 1018
Blood glucose, 998
Blood group
agglutination index, 1051
ultraviolet and visible light spectrophotometry, 1051
Blood group serology, 364
Blood group typing
chronically transfused patient, mixed-field agglutination, 852
lectin, 1060
RHCE genotyping, 852
  polymerase chain reaction, 852
RHD genotyping, 852
  polymerase chain reaction, 852
Blood loss
acute normovolemic hemodilution, 396
anemia, 396
erythropoietin, 392
hematocrit, 392
Blood pressure, blood donor, 316
Blood substitute, 1027
Blood transfusion. *See* Transfusion
Blood type, agglutination index, 1051
Blood typing, ultraviolet and visible light spectrophotometry, 1051
Blood volume
acute normovolemic hemodilution, 396
erythropoietin, 392
hematocrit, 392
Blood-borne virus
GB virus type C/hepatitis G virus anti-E2, 83
GB virus type C/hepatitis G virus RNA, 83
high risk, 83
low risk, 83
Bone marrow transplantation, 83
See also Allogeneic bone marrow transplantation; Autologous bone marrow transplantation
dextran sedimentation, 1212
engraftment, 1212
ficoll, 1212
hematopoietic progenitor cell, 1212
minor ABO incompatibility, 824

red cell, ... 1212
Bone pain, granulocyte–colony-stimulating factor
acid phosphatase, ... 410
bone-specific alkaline phosphatase, ... 410
osteocalcin, ... 410
tartrate-resistant acid phosphatase, ... 410
Bone-specific alkaline phosphatase, ... 410
Bovine spleen galectin, *Aplysia* gonad lectin, ... 1060
Bovine viral diarrhea virus
ethanol precipitation, ... 249
pasteurization, ... 249
BPF4 filter, temperature, ... 265
Bradykinin
angiotensin-converting enzyme, ... 1084
bedside white cell-reduction filter, ... 1084
enalaprilat, ... 1084
hypotensive reaction, ... 107(L)
transfusion complication, ... 1084
Brazil
Chagas' disease, ... 711
hemophiliac, ... 1194
hepatitis C virus genotype, ... 1194
human immunodeficiency virus, estimated risk, ... 1152
Breast cancer, ... 442
large-volume leukapheresis, ... 1120
normal-volume leukapheresis, ... 1120
pooled random-donor platelet, ... 925
single-donor platelet, ... 925
5-Bromodesoxyuridine, tumor cell, ... 608
Buccal mucosa, DNA, polymerase chain reaction-restriction fragment length polymorphism, ... 1247
Buffy coat-depleted blood component
allogeneic transfusion, ... 625
autologous transfusion, ... 625
orthopedic surgery, ... 625
postoperative infection, ... 625
transfusion complication, ... 625
Buffy coat-depleted red cell
helper T cell, ... 1089
mixed lymphocyte culture, ... 1089
phytohemagglutinin, ... 1089
suppressor T cell, ... 1089
T cell, ... 1089
T-cell proliferation, ... 1089
transfusion complication, ... 1089
Buffy coat-depleted saline-adenine-glucose-mannitol blood, soluble vascular endothelial growth factor, ... 1078
Buffy coat-derived platelet pool, soluble vascular endothelial growth factor, ... 1078

C

C1 Fab fragment, ... 364
C3a, ... 271
C5b-9 terminal complement complex, ... 271
C302T mutation, Thai population, ... 1013
Canada, hepatitis C virus lookback, ... 194
Cardiac surgery, transfusion triggers, ... 1070
CD3+ cell, allogeneic red cell, ... 1089
CD4+
acute retroviral syndrome, ... 383
AIDS, ... 383
immunosilent AIDS, ... 383
CD8+ cell, allogeneic buffy coat-depleted red cell, ... 1089
CD11b, ... 527
CD16, ... 527
CD34, flow cytometry, ... 1220
CD34+ cell, ... 403, 1200, 1207
acute myeloid leukemia, ... 442
apheresis
cell count predictive value, ... 442
maximizing yield, ... 442
automated apheresis system, ... 48
CD34+ cell collection efficiency, ... 48
cell composition, ... 48
patient platelet and red cell loss during leukapheresis, ... 48
platelet collection efficiency, ... 48
volume, ... 48
AutoPBSC, ... 48
CD34+ cell collection efficiency, ... 48
cell composition, ... 48
patient platelet and red cell loss during leukapheresis, ... 48
platelet collection efficiency, ... 48
volume, ... 48
CellQUEST software, ... 1220
dextran sedimentation, ... 1212
filgrastim, ... 442
flow cytometry, ... 856, 864
granulocyte–colony-stimulating factor, ... 39, 561
granulocyte-macrophage–colony-stimulating factor, ... 39
immunohematology, ... 864
international study, ... 856
standardization of CD34+ cell enumeration, ... 856
large-volume leukapheresis, ... 1120
leukapheresis, ... 403
measurement, ... 1220
microvolume fluorimetry method, ... 856
mononuclear cell, ... 403
normal-volume leukapheresis, ... 1120
optimal growth factor dosing, ... 39
ProCOUNT kit, ... 1220
ProCOUNT software, ... 1220
transplantation, semi-automated flow cytometric analysis, ... 1220
volumetric capillary cytometry, ... 864
white cell, ... 403
CD35, ... 527
CD36
Asian, ... 873
French, ... 873
white European patient, ... 873
CD36 deficiency
African
frequency, ... 873
platelet immunization, ... 873
immunohematology, ... 873
sub-Saharan African, ... 873
CD40, ... 818
CD40L, ... 818
CD41
AMICUS cell separator, ... 74
flow cytometry, ... 74
storage, ... 74
CD42b
AMICUS cell separator, ... 74
flow cytometry, ... 74
storage, ... 74
CD62, white cell reduction, ... 724
CD62p-positive platelet
AMICUS cell separator, ... 74
flow cytometry, ... 74
storage, ... 74
CD63, white cell reduction, ... 724
CD63-positive platelet
AMICUS cell separator, ... 74
flow cytometry, ... 74
storage, ... 74
CD154, ... 818
human-peripheral blood lymphocyte-severe combined immune-deficient mice
alloimmunization, ... 818
HLA-specific alloantibody, ... 818
IgG, ... 818
T cell, ... 818
cE polypeptide, ... 17
Cefotaxime
immune hemolytic anemia, ... 1239
neutropenia, ... 527

granulocyte agglutination test, ... 527
monoclonal antibody-specific immobilization of granulocyte antigens assay, ... 527
Cefotetan, immune hemolytic anemia, ... 1239
Cefoxitin, immune hemolytic anemia, ... 1239
Ceftizox, ... 838
Ceftizoxime
immune hemolytic anemia, ... 838
immunohematology, ... 306
Ceftriaxone, immune hemolytic anemia, ... 1239
Cell separator. *See also* Specific type
elutriation principle, ... 572
in-line filtration, ... 572
periodically alternating interface position, ... 572
platelet antigen, ... 742
white cell reduction, compared, ... 572
CellQUEST software, CD34+ cell, ... 1220
Cellselect FR filter, temperature, ... 265
Cellselect Optima Plus filter, temperature, ... 265
Cephalosporin, ... 306
direct antiglobulin test, ... 1239
immune hemolytic anemia, serology of antibodies, ... 1239
immunohematology, ... 1239
indirect antiglobulin test, ... 1239
Cephem, ... 306
hemolytic anemia, ... 306
Chagas' disease
Brazil, ... 711
Latin America, ... 711
recombinant peptide antigen line immunoassay, ... 711
Chemiluminescent immunoassay, hepatitis B surface antigen, ... 660(L)
Chemokine RANTES, nonhemolytic transfusion reaction, ... 1179
Chills, therapeutic apheresis, ... 282
Chimpanzee model, human immunodeficiency virus, seronegative window, ... 688
China
α(1,2)-fucosyltransferase gene mutation, ... 1013
hepatitis C virus, ... 913(L)
Chronic hepatitis, ... 522
Chronic lymphocytic leukemia
anti-c, ... 763
anti-E, ... 763
antigen matching, ... 763
anti-K, 763
Rh system antibody, ... 763
Chronic myelogenous leukemia, ... 179, 387
bcr/abl translocation, ... 387
granulocytopenia, ... 387
pooled random-donor platelet, ... 925
single-donor platelet, ... 925
Chronically transfused patient, blood group typing, mixed-field agglutination, ... 852
Circulatory collapse, ... 998
Citrate
activated factor VII, ... 1266
activated hemostasis, ... 1266
antithrombin, ... 1266
automated plasmapheresis, prospective study, ... 1266
β-thromboglobulin, ... 1266
blood collection, ... 1266
clotting factor, ... 1266
D-dimer, ... 420, 1266
factor V, ... 1266
factor VII, ... 1266
factor VIII, ... 1266
factor IX, ... 1266
fibrinogen, ... 1266
fibrinolysis, ... 1266
lymphocyte, ... 420
monocyte, ... 420
mononuclear cell, ... 420
plasminogen activator inhibitor, ... 420
plasmin-plasmin inhibitor complex, ... 420
platelet-neutrophil aggregate, ... 420
prothrombin fragment, ... 420
prothrombin splits product, ... 1266
therapeutic apheresis, ... 282
tissue-type plasminogen activator, ... 1266
Clinical Laboratory Science Education & Management, book review, ... 435
Clotting factor, ... 1227
citrate, ... 1266
fresh-frozen plasma, storage to 24 hours, ... 488
solvent/detergent-treated plasma, ... 1150(L)
storage, 8 *vs.* 24 hours, ... 488
temperature, ... 488
Clotting factor.
See also Specific type
Coagulation
AMICUS cell separator, ... 420
elutriation, ... 975
Coagulation deficit, ... 1227
COBE Spectra, white cell-reduced apheresis platelet, ... 960
Cold agglutinin, ... 295
Colony-forming unit, dextran sedimentation, ... 1212
Colony-forming units/196granulocyte-macrophage
large-volume leukapheresis, ... 1120
normal-volume leukapheresis, ... 1120
Committee report, use of blood therapeutically drawn from hemochromatosis patients, ... 1018
Common variable immune deficiency, ... 83
Complement activation
innocent-bystander mechanism, ... 944
white cell reduction, ... 724
Complement receptor 1 red cell expression, immunohematology, ... 751
Complement-specific antiglobulin reagent
anti-Tc^a, ... 948
Cromer system antibody, ... 948
Congenital anemia, ... 852
Cord blood
donor criteria, ... 415
efficacy, ... 415
I antigen, ... 1060
maternalCneonatal donor pair, ... 415
deferral factors, ... 415
safety, ... 415
volumetric capillary cytometry, ... 864
Cord blood banking, ... 357
cost, ... 645
centralized banking, ... 645
cost recovery after 10 years, ... 645
flexible collection, ... 645
models, ... 645
standard operating procedures, ... 357
Coronary artery bypass graft
hemoglobin, ... 1070
fatigue, ... 1070
hemoglobin threshold level, ... 1070
morbidity, ... 1070
mortality, ... 1070
patient outcome, ... 1070
pooled random-donor platelet, ... 925
postoperative pneumonia, red cell storage time, ... 701
red cell, ... 701
number of units, ... 701
storage time, ... 701
single-donor platelet, ... 925
transfusion, ... 1070
Corrected count increment, platelet transfusion
potential for data distortion, ... 586
regression analysis, ... 586
Cost-effectiveness
autologous transfusion, ... 808
limited-donor program, ... 938
plasma, ... 479

recombinant human erythropoietin, 933
single-donor platelet, 925
virus-inactivated plasma, 479
Cost-utility analysis, 808
Counterflow centrifugal elutriation, monocyte, 975
CPDA-1 blood preservative
hemorrhage, massive resuscitation, 998
swine model, 998
transfusion practice, 998
^{51}Cr
biotin, compared, 149
red cell, 149
measuring circulating red cell volume, 149
measuring red cell survival, 156
Creutzfeldt-Jakob disease, 919(E)
blood component, 1169
lookback, 540(L)
solvent/detergent-treated frozen plasma, 107(L)
white cell reduction, 107(L)
Cromer system antibody
complement-specific antiglobulin reagent, 948
differential typing, 948
direct antiglobulin test, 948
haptoglobin, 948
hemoglobin, 948
lactate dehydrogenase, 948
monocyte monolayer assay, 948
Tc(a+) red cell, 948
Cryopreserved platelet
activated glycoprotein IIb/IIIa, 880
adhesive surface receptors, 880
factor V, 880
glycoprotein Ib, 880
membrane procoagulant activity, 880
p-selectin, 880
Cytokine
erythropoiesis, 271
febrile nonhemolytic transfusion reaction, 231
filtered whole blood, 271
platelet concentrate
photochemical treatment, 239
psoralen plus ultraviolet A light, 239
red cell, 718
storage, 239
washed red cell, 271
white cell reduction, 718
Cytomegalovirus
neonate, 201
white cell
endemic area, 201
filtered-irradiated blood, 201
newborn infant, 201
nonfiltered-irradiated blood, 201
white cell-reduction filtration, 201

D

D antigen
exofacial domains, 17
fetomaternal red cell alloimmunization
cord blood hemoglobin, 169
gestational age, 169
hematocrit, 169
intrauterine transfusions, 169
male/female fetuses compared, 169
perinatal mortality, 169
immunohematology, 17
membrane-spanning segments, 17
D blood type, agglutination index, 1051
D epitope, 17, 1005
Ala_{354}, 17
Asp_{350}, 17
expression, 17
Gly_{353}, 17
mapping, 17
D+ fetus, 1235
D monoclonal antibody
immunohematology, 1005
lymphocyte (K-cell) antibody-dependent cell-mediated cytotoxicity, 1005
monocyte antibody-dependent cell-mediated cytotoxicity, 1005
monocyte chemiluminescence, 1005
D-- phenotype
hemolytic disease of newborn, 1151
pregnancy, 1151
D typing
gel agglutination assay, 300
immunohematology, 300
Data acquisition, quality improvement, 351
D-Dimer
AMICUS cell separator, 420
citrate, 420, 1266
MCS 3p cell separator, 420
Decision analysis model
pooled random-donor platelet, 925
single-donor platelet, 925
Decision tree analysis, recombinant human erythropoietin, 933
Delayed hemolytic transfusion reaction
incidence changes, 1097
transfusion complication, 1097
Dendritic cell, Spectra apheresis system, 661(L)
Denmark
hepatitis C virus lookback, 188
NA1, 593
NA2, 593
SH, 593
des-Arg^9-bradykinin metabolism
angiotensin-converting enzyme, 1084
bedside white cell-reduction filter, 1084
enalaprilat, 1084
transfusion complication, 1084
Desmopressin acetate, 1027
Dextran sedimentation
bone marrow, 1212
CD34+ cell, 1212
colony-forming unit, 1212
flow cytometry, 1212
long-term culture, 1212
long-term culture-initiating cell, 1212
mononuclear cell, 1212
nucleated cell, 1212
red cell, 1212
short-term culture, 1212
transplantation, 1212
Diabody-based hemagglutination assay, HPA-1a phenotyping, 781
DiaMed-ID
antibody reactivity, 1045
anti-Le^a antibody, 1045
anti-Le^b antibody, 1045
anti-M antibody, 1045
anti-N antibody, 1045
anti-P_1 antibody, 1045
tube low-ionic-strength solution indirect antiglobulin test, compared, 1045
Diaphoresis, therapeutic apheresis, 282
Di(b+) red cell, 163
Differential typing
anti-Tc^a, 948
Cromer system antibody, 948
Dilutional coagulopathy
activated partial thromboplastin time, tests compared, 56
prothrombin, tests compared, 56
Dimethyl sulfoxide
blood component, 70
platelet, 616
Direct antiglobulin test
anti-Tc^a, 948

cephalosporin, 1239
Cromer system antibody, 948
Disseminated intravascular coagulation, 231
Dithiothreitol, 1065
Dithiothreitol and enzyme reagent, 11
Diuresis, 998
DNA
buccal mucosa, polymerase chain reaction-restriction fragment length polymorphism, 1247
peripheral blood, polymerase chain reaction-restriction fragment length polymorphism, 1247
Documentation
lookback and traceback procedures, 351
quality, 351
Dose-response relationship
bacterial infection, 694
platelet transfusion, 674
prospective randomized double-blind multiple-crossover study, 674
Drug-induced hemolytic reaction, deftizoxime, 838
Drug-induced neutropenia, 527

E

Echovirus, 1041
Education, inappropriate preoperative autologous blood donation, 801
Ehrlichiosis, 828
807 C/T polymorphism, platelet glycoprotein Ia molecule, 372
Elderly patient, preoperative autologous blood donation
accessible superficial vein, 174
allogeneic blood, 174
anemia, 174
cardiovascular complication, 174
incidence of complications, 174
vasovagal reaction, 174
Elutriation
coagulation, 975
lipopolysaccharide, 975
tissue factor, 975
tissue factor expression, 975
tissue factor pathway inhibitor, 975
Encephalomyocarditis virus
ethanol precipitation, 249
pasteurization, 249
Endothelial cell monolayer, hydroxyethyl starch, 289
Engraftment
large-volume leukapheresis, 1120
normal-volume leukapheresis, 1120
Enzyme-linked immunosorbent assay, 1104
Fab fragment, 364
human T-cell lymphotropic virus type I
sensitivity, 1185
specificity, 1185
human T-cell lymphotropic virus type II
sensitivity, 1185
specificity, 1185
IgG anti-D, 515
IgG subclass concentration, 515
immunoglobulin, 515
international reference preparation coded 68/419, 515
soluble vascular endothelial growth factor, 1078
Epitope mapping, 1(E)
Erythrina corallodendron lectin, *Aplysia* gonad lectin, 1060
Erythroid aplasia, 179
Erythroid–burst-forming unit, progenitor assay, 451
Erythropoiesis, cytokine, 271
Erythropoietin, 899, 933
blood loss, 392
blood volume, 392
hematocrit, 392
hemodilution, 392
red cell, 392
Erythro-Sol, 565
Ethanol precipitation
bovine viral diarrhea virus, 249
encephalomyocarditis virus, 249
human immunodeficiency virus, 249
immune globulin, 249
pseudorabies virus, 249
Sindbis virus, 249
vaccinia virus, 249
vesicular stomatitis virus, 249
Ethical issues, hereditary hemochromatosis, 1018
Ethylene glycol, platelet, 616
Exchange transfusion, 26
EXCORIM
acetylcholine receptor, 682
autoimmune disorder, 682
IgG antibody, 682
myasthenia gravis, 682
Exon-specific polymerase chain reaction, *RH* gene, 1259

F

Fab fragment, 364
agglutination, 364
enzyme-linked immunosorbent assay, 364
light-chain shuffling, 364
Factor V, 56
citrate, 1266
cryopreserved platelet, 880
fresh platelet, 880
fresh-frozen plasma, 488
liquid-preserved platelet, 880
Factor Va, platelet concentrate preparation, 951
Factor VII
citrate, 1266
fresh-frozen plasma, 488
Factor VIII, 56
citrate, 1266
fresh-frozen plasma, 488
solvent/detergent-treated fresh-frozen plasma, 1227
Factor VIII/von Willebrand factor molecular complex, methylene blue, 748
Factor IX, 56
citrate, 1266
Factor IX complex
hepatitis B virus, 1160
hepatitis C virus, 1160
human immunodeficiency virus type I, 1160
virus transmission, 1160
Factor X, fresh-frozen plasma, 488
Factor XIII, methylene blue, 748
Fatigue, 1070
FcγRIIIB polymorphism
NA1, 593
NA2, 593
SH, 593
Febrile nonhemolytic transfusion reaction, 231
aminomethyltrimethyl psoralen, 239
cytokine, 231
γ-radiation, 239
interleukin 6, 231
8-methoxypsoralen, 239
plasma depletion, 231
platelet, 231
poststorage white cell reduction, 231
psoralen, 239
randomized controlled trial, 231
S-59, 239
ultraviolet A light, 239
white cell-poor platelet preparation, 1179
Fetus
alloimmunization to D
cord blood hemoglobin, 169
fetal hemolysis, 1235
gestational age, 169

hematocrit, ... 169
immunoglobulin, ... 1235
intrauterine transfusions, ... 169
male/female fetuses compared, ... 169
outcome, ... 1235
perinatal mortality, ... 169
pregnancy, ... 1235
anemia, ... 149, 156
fetal hemolysis, ... 1235
immunoglobulin, ... 1235
outcome, ... 1235
pregnancy, ... 1235
anti-G, ... 531
I antigen, ... 1060
Fibrinogen, ... 277
AMICUS cell separator, ... 74
citrate, ... 1266
flow cytometry, ... 74
fresh-frozen plasma, ... 488
methylene blue, ... 748
platelet concentrate preparation, ... 951
storage, ... 74
Fibrinolysis
AMICUS cell separator, ... 420
citrate, ... 1266
white cell reduction, ... 724
Fibronectin, platelet concentrate preparation, ... 951
Ficoll
bone marrow, ... 1212
progenitor assay, ... 451
Filgrastim
apheresis
adverse events, ... 555
apheresis-related adverse events, ... 555
bone pain, ... 555
CD34+ cell dose collected, ... 555
fatigue, ... 555
headache, ... 555
nausea, ... 555
preapheresis white cell count, ... 555
safety, ... 555
CD34+ cell, ... 442
peripheral blood progenitor cell, safety, ... 555
Filtration
biologic response modifier, ... 498
platelet activation, ... 498
platelet component, ... 498
RANTES, ... 498
transforming growth factor-β, ... 498
Flow cytometry
CD34, ... 1220
CD34+ cell, ... 856, 864
CD41, ... 74
CD42b, ... 74
CD62p-positive platelet, ... 74
CD63-positive platelet, ... 74
dextran sedimentation, ... 1212
fibrinogen binding, ... 74
granylocyte antibody, ... 983
IgG, ... 756
IgM, ... 756
immunoglobulin isotype identification, ... 756
protocols, ... 864
volumetric capillary cytometry, compared, ... 864
Fluidized particle-bed separation, white cell-reduced apheresis platelet, ... 960
Fluorescein, platelet, ... 616
ADP, ... 616
p-selectin, ... 616
ristocetin, ... 616
thrombin, ... 616
Fluorescein isothiocyanate, ... 1220
Fluorescent treponemal antibody absorption test, syphilis, ... 206
Food and Drug Administration
blood component recall, ... 439(E), 473
effectiveness, ... 440(E)
elements, ... 440(E)
philosophy and policy, ... 440(E)
process, ... 440(E)
reasons for notification, ... 440(E)
recall authority, ... 439(E)
Investigational New Drug license
donor recruitment, ... 357
reporting of positive infectious disease, ... 357
sample tracking, ... 357
transplant recipient outcome data collection, ... 357
use of unlicensed materials, ... 357
France
GB virus type C/hepatitis G virus anti-E2, ... 95
GB virus type C/hepatitis G virus RNA, ... 95
human immunodeficiency virus type ... 1, 1141
recombinant human erythropoietin, ... 933
French West Indies, human T-cell lymphotropic virus type I
biologic characteristics, ... 639
demographic characteristics, ... 639
donation characteristics, ... 639
seriondeterminate patterns, ... 1145
seroconversions, ... 1145
Fresh platelet
activated glycoproteinIIb/IIIa, ... 880
adhesive surface receptors, ... 880
factor V, ... 880
glycoprotein Ib, ... 880
membrane procoagulant activity, ... 880
p-selectin, ... 880
Fresh-frozen plasma
antithrombin III, ... 488
clotting factor, storage to 24 hours, ... 488
factor V, ... 488
factor VII, ... 488
factor VIII, ... 488
factor X, ... 488
fibrinogen, ... 488
liver disease coagulopathy, ... 1227
liver transplantation, ... 1227
preparation, ... 488
protein C, ... 488
protein S, ... 488
storage, 8 *vs.* 24 hours, ... 488
temperature, ... 488
transfusion practice, ... 1227
α (1,2)-Fucosyltransferase gene mutation
Chinese population, ... 1013
immunohematology, ... 1013
Thai population, ... 1013

G

G11 Fab fragment, ... 364
Galactophilic lectin, *Aplysia* gonad lectin, ... 1060
α-Galactosidase, NOR polyagglutination, ... 32
Gamma radiation
AS-1 red cell
hemolysis, ... 128
potassium, ... 128
red cell ATP, ... 128
storage time, ... 128
viability, ... 128
in vitro properties, ... 128
biologic response modifier, ... 498
febrile nonhemolytic transfusion reaction, ... 239
interleukin ... 8, 239
platelet activation, ... 498
platelet component, ... 498
RANTES, ... 498
transforming growth factor-β, ... 498
tumor cell, ... 608

survival curves, 608
Gamma ReACT
antibody reactivity, 1045
anti-Le^a antibody, 1045
anti-Le^b antibody, 1045
anti-M antibody, 1045
anti-N antibody, 1045
anti-P$_1$ antibody, 1045
tube low-ionic-strength solution indirect antiglobulin test, compared, 1045
GB hepatitis virus, 1041
GB virus type C, 790(L)
acute lymphoblastic leukemia, 212
alanine aminotransferase, 212
anti-E2, 212
hepatitis C virus, 212
non-Hodgkin's lymphoma, 212
alanine aminotransferase, 212
anti-E2, 212
GB virus type C/hepatitis G virus anti-E2
blood-borne virus, 83
France, 95
health care workers, 95
molecular marker, 95
parenteral transmission, 83
phylogenetic distribution of viral strains, 95
serologic marker, 95
sexual transmission, 83
sexually transmitted virus, 83
tattooed or pierced individuals, 95
transfusion complication, 83, 95
virus transmission, 83
GB virus type C/hepatitis G virus RNA, phylogenetic distribution of viral strains, 95
blood-borne virus, 83
France, 95
health care workers, 95
molecular marker, 95
parenteral transmission, 83
serologic marker, 95
sexual transmission, 83
tattooed or pierced individuals, 95
transfusion complication, 83, 95
virus transmission, 83
Gel agglutination assay
ABO grouping, 300
B isohemagglutinin, 300
D typing, 300
tube agglutination, 300
weak A, 300
weak B, 300
weak D, 300
Gene therapy, 343
Genetics, hereditary hemochromatosis, 1018
Genomic analysis, ABO mosaicism, 1247
Genotype 1, hepatitis C virus, 1194
Genotype 3, hepatitis C virus, 1194
Genotype lineage, hepatitis C virus, 1194
Genotyping, 852
German reference protocol for analysis of CD34-expressing cells, 1220
Germany, accuracy of data records, 351
Glucose, 998
platelet, 616
Gly_{353}, D epitope, 17
Glycerol, platelet, 616
Glycolipid
NOR polyagglutination, 32
St^a glycophorin, 32
Glycophorin
NOR polyagglutination, 32
St^a glycophorin, 32
Glycoprotein Ia gene, 372
Glycoprotein Ib
cryopreserved platelet, 880
fresh platelet, 880
liquid-preserved platelet, 880
Graft-vs-host disease, 179
Granulocyte
aluminum phthalocyanine tetrasulfonate, 599
annexin V, 599
phthalocyanine, 599
prodidium iodide, 599
storage, 983
Granulocyte activation
MCS+, 735
plateletpheresis instrument, 735
Granulocyte agglutination test, 944
Granulocyte alloantigen, nomenclature, 662(L)
Granulocyte i–3b receptor, 735
Granulocyte immunofluorescence test, 944
Granulocyte–colony-stimulating factor
blood donor, 1136
bone pain
acid phosphatase, 410
bone-specific alkaline phosphatase, 410
osteocalcin, 410
tartrate-resistant acid phosphatase, 410
CD34+ cell, 561
chemopriming treatment, 1207
chemotherapy, 561
effect on potential normal granulocyte donors, 1136
neutropenia, 527
neutrophil, 1136
optimal time, 561
osteoblastic activity, 410
peripheral blood progenitor cell, 1136, 1207
CD34+ cell, 1207
number of leukapheresis procedures, 1207
optimal dose, 1207
retrospective study, 1207
progenitor assay, 451
side effects, 1136
unstable angina, 542(L)
Granulocyte-agglutinating antibody, paroxysmal nocturnal hemoglobinuria
hemolysis, 944
renal failure, 944
transfusion-related acute lung injury, 944
Granulocyte-macrophage–colony-stimulating factor
granulocyte–colony-stimulating factor, 39
Granulocytopenia, chronic myelogenous leukemia, 387
Granylocyte antibody
blood component, 983
flow cytometric analysis, 983
immunofluorescence method, 983
indirect immunofluorescence assay, 983
methods for detection, 983
Griffonia simplicifolia IB4 lectin
NOR polyagglutination, 32
St^a glycophorin, 32
Group O red cell, 1065
Guadeloupe, human T-cell lymphotropic virus type I
biologic characteristics, 639
demographic characteristics, 639
donation characteristics, 639
Guide to the Preparation, Use and Quality Assurance of Blood Components, book review, 547

H

Haptoglobin
anti-Tc^a, 948
Cromer system antibody, 948
Helper T cell
buffy coat-depleted red cell, 1089
white cell filtered red cell, 1089

Hemagglutination, ... 163
  IgG anti-D, ... 515
Hematocrit
  acute normovolemic hemodilution, ... 396
  anemia, ... 396
  blood loss, ... 392
  blood volume, ... 392
  erythropoietin, ... 392
  hemodilution, ... 392
  intravenous fetal immunoglobulin, ... 1235
  red cell, ... 392
  two-unit red cell apheresis, ... 218
Hematologic disease, immunohematology, ... 763
Hematopoietic colony-derived DNA
  ABO chimera, ... 1247
  ABO mosaicism, ... 1247
Hematopoietic growth factor
  automated plateletpheresis
    erythropoietin, ... 899
    interleukin-1β, ... 899
    interleukin-6, ... 899
    stem cell factor, ... 899
    systemic levels, ... 899
    thrombopoietin, ... 899
  blood collection, ... 899
  platelet, ... 321
Hematopoietic progenitor cell, ... 179
  blood component, ... 70
  bone marrow, ... 1212
  platelet transfusion, ... 674
  pooled random-donor platelet, ... 925
  recruitment, ... 403
  single-donor platelet, ... 925
  storage
    5- vs 10-percent dimethyl sulfoxide, ... 70
    burst-forming units–erythroid, ... 70
    colony-forming units–granulocyte-macrophage, ... 70
    lengths of storage time, ... 70
    mononuclear cell, ... 70
  temperature
    burst-forming units–erythroid, ... 70
    colony-forming units–granulocyte-macrophage, ... 70
    mononuclear cell, ... 70
Hematopoietic system, ... 899
Hemochromatosis, therapeutic phlebotomy
  amount of blood withdrawn, ... 651
  charges, ... 651
  insurance coverage, ... 651
  patterns, ... 651
  phlebotomy site, ... 651
  rates of withdrawal, ... 651
  time since diagnosis, ... 651
Hemochromatosis proband
  alanine aminotransferase, ... 578
  volunteer white whole-blood donors compared, ... 578
Hemodilution, ... 1027
  erythropoietin, ... 392
  hematocrit, ... 392
Hemoglobin, ... 271
  AmpliScreen Hepatitis C (HCV) Test, ... 1111
  anti-Tc^a, ... 948
  autologous blood donation, ... 801
  blood component, ... 226(L)
  coronary artery bypass graft, ... 1070
    fatigue, ... 1070
    hemoglobin threshold level, ... 1070
    morbidity, ... 1070
    mortality, ... 1070
    patient outcome, ... 1070
  Cromer system antibody, ... 948
  filtered whole blood, ... 271
  plateletpheresis, ... 790(L)
  transfusion, ... 1070
  washed red cell, ... 271
Hemolysis, ... 128, 179, 944
  albumin, diluted with sterile water, ... 110(L)
  epitope responsible, ... 306
Hemolytic anemia, ... 306
  cephem, ... 306
  penicillin, ... 306
Hemolytic disease of the newborn, ... 26, 515
  anti-At^a, ... 834
  anti-C, ... 531
  anti-D, ... 531
  anti-G, ... 531
  anti-Go^a, ... 537(L)
  anti-Hr$_O$, ... 1151
  D-- phenotype, ... 1151
Hemolytic transfusion reaction
  anti-At^a, ... 834
  anti-Tc^a, ... 948
  deftizoxime, ... 838
Hemophiliac
  Brazil, ... 1194
  hepatitis C virus genotype, ... 1194
  immune tolerance, ... 1034(L)
Hemorrhage
  Adsol blood preservative, massive resuscitation, ... 998
  CPDA-1 blood preservative, massive resuscitation, ... 998
Hemorrhagic shock, animal model, ... 998
Hemostasis
  activated partial thromboplastin time, ... 56
  platelet, ... 967
  prothrombin, ... 56
Hepatitis A virus, ... 1227
Hepatitis B surface antigen, chemiluminescent immunoassay, .. 660(L)
Hepatitis B virus, ... 1227
  albumin, ... 1160
  AmpliScreen Hepatitis C (HCV) Test, ... 1111
  antihemophilic factor, ... 1160
  factor IX complex, ... 1160
  immune globulin product, ... 1160
  plasma derivative, ... 1160
  pooled random-donor platelet, ... 925
  reverse transcriptase polymerase chain reaction, ... 1111
  single-donor platelet, ... 925
  transfusion complication, ... 1111
  virus-inactivated plasma, ... 479
Hepatitis C virus, ... 1227
  albumin, ... 1160
  AmpliScreen Hepatitis C (HCV) Test, ... 1111
  antihemophilic factor, ... 1160
  China, ... 913(L)
  Danish lookback experience, ... 188
  factor IX complex, ... 1160
  GB virus type C, ... 212
  genotype
    Brazil, ... 1194
    hemophiliac, ... 1194
    restriction fragment length polymorphism analysis, 5' noncoding region, ... 1194
  genotype 1, ... 1194
  genotype 3, ... 1194
  genotype lineage, ... 1194
  immune globulin, ... 249
  immune globulin product, ... 1160
  lookback, ... 123(E)
  non-Hodgkin's lymphoma, ... 212
  nucleic acid testing, Food and Drug Administration workshop, ... 912(L)
  plasma derivative, ... 1160
  pooled random-donor platelet, ... 925
  Quebec, Canada lookback, ... 194
  recombinant immunoblot assay
    anti-NS5, ... 790(L)
    GB virus type C, ... 790(L)

hepatitis G virus, ... 790(L)
reverse transcriptase polymerase chain reaction, ... 1111
single-donor platelet, ... 925
subtype 1a, ... 1194
third-generation recombinant immunoblot assay, ... 335(L)
transfusion complication, ... 1111
genotypes, ... 1194
virus-inactivated plasma, ... 479
Hepatitis C virus RNA
AmpliScreen Hepatitis C (HCV) Test, ... 1111
reverse transcriptase polymerase chain reaction, ... 1111
transfusion complication, ... 1111
Hepatitis G virus, ... 790(L), 1041
envelope antibodies, ... 633
HGV RNA, ... 633
immunoglobulin product, manufactured in Europe, ... 428(L)
thalassemic patient, ... 336(L)
Hepatitis G virus E2 antigen, immunoglobulin product, ... 1271(L)
Hepatitis GB virus type C, thalassemic patient, ... 336(L)
Hereditary hemochromatosis, ... 1018
altruistic intent, ... 1018
blood usage, ... 549, 551
clinical features and diagnosis, ... 1018
ethical issues, ... 1018
external factors, ... 1018
genetics, ... 1018
treatment, ... 1018
voluntary blood donation, ... 1018
High-risk maternal population, cord blood donor, ... 415
Hip fracture, ... 694
HLA class I antibody, ... 772
HLA sensitization
apheresis, female donors, ... 103
parity, ... 103
plateletpheresis donor, ... 103
screening, ... 103
transfusion-related acute lung injury, ... 103
HLA-specific alloantibody, ... 818
Homosexual men, ... 83
HPA-1a phenotyping
diabody-based hemagglutination assay, ... 781
immunohematology, ... 781
recombinant IgG1-based assay, ... 781
HPA-5 polymorphism, platelet glycoprotein Ia molecule, ... 372
HPA-5b antibody
monoclonal antibody-specific immobilization of platelet antigen, ... 379
neonatal alloimmune thrombocytopenia
IgG titer, ... 379
light-chain phenotype, ... 379
subclass, ... 379
HTLV-I. *See* Human T-cell lymphotropic virus type I
Human anti-I, ... 1060
Aplysia gonad lectin, ... 1060
Human immunodeficiency virus, ... 473, 1227
albumin, ... 1160
Brazil, estimated risk, ... 1152
chimpanzee model, seronegative window, ... 688
ethanol precipitation, ... 249
immune globulin product, ... 1160
nucleic acid testing, seronegative window, ... 688
pasteurization, ... 249
pooled random-donor platelet, ... 925
single-donor platelet, ... 925
virus-inactivated plasma, ... 479
Human immunodeficiency virus p24 antigen assay
acute retroviral syndrome, ... 383
AIDS, ... 383
immunosilent AIDS, ... 383
Human immunodeficiency virus polymerase chain reaction
acute retroviral syndrome, ... 383
AIDS, ... 383
immunosilent AIDS, ... 383
Human immunodeficiency virus type I
AmpliScreen Hepatitis C (HCV) Test, ... 1111
antihemophilic factor, ... 1160
factor IX complex, ... 1160
France, ... 1141
nucleic acid amplification testing, ... 1141
plasma derivative, ... 1160
reverse transcriptase polymerase chain reaction, ... 1111
simulation model, ... 1141
transfusion complication, ... 1111
window period, ... 1141
Human monoclonal anti-D, ... 1005
Human parvovirus B19, ... 1227
Human T-cell lymphotropic virus, *tax* gene, ... 795(E)
Human T-cell lymphotropic virus antibody assay, ... 845
Human T-cell lymphotropic virus type I
blood donor, ... 1145
donor screening, efficacy, ... 1104
enzyme immunoassay
sensitivity, ... 1185
specificity, ... 1185
transfusion complication, ... 845
French West Indies
biologic characteristics, ... 639
demographic characteristics, ... 639
donation characteristics, ... 639
seriondeterminate patterns, ... 1145
seroconversions, ... 1145
Guadeloupe
biologic characteristics, ... 639
demographic characteristics, ... 639
donation characteristics, ... 639
inner-city emergency department, ... 1185
Japan, ... 1104
lookback investigation, ... 1145
natural history of transfusion-transmitted infection, ... 1104
polymerase chain reaction
sensitivity, ... 1185
specificity, ... 1185
pooled random-donor platelet, ... 925
seroconversion, ... 1104
adult T-cell lymphoma, ... 1104
enzyme-linked immunosorbent assay, ... 1104
human T-cell lymphotropic virus type I associated myelopathy, ... 1104
immunoblotting, ... 1104
immunofluorescence assay, ... 1104
nested polymerase chain reaction, ... 1104
second-generation particle agglutination test, ... 1104
uveitis, ... 1104
single-donor platelet, ... 925
transfusion complication, ... 1104, 1185
type-specific Western blot assay
sensitivity, ... 1185
specificity, ... 1185
Western blot assay
indeterminate, ... 1145
sensitivity, ... 1185
specificity, ... 1185
Human T-cell lymphotropic virus type I *tax* sequence
blood collection, ... 904
multicenter blind study, ... 904
normal blood donors in Baltimore, MD/Washington, DC area, ... 904
polymerase chain reaction analysis, ... 904
analytical sensitivity, ... 904
Human T-cell lymphotropic virus type I-associated myelopathy, ... 1104, 1185
pooled random-donor platelet, ... 925
single-donor platelet, ... 925
Human T-cell lymphotropic virus type II
enzyme immunoassay
sensitivity, ... 1185

specificity, ... 1185
inner-city emergency department, ... 1185
polymerase chain reaction
sensitivity, ... 1185
specificity, ... 1185
transfusion complication, ... 1185
type-specific Western blot assay
sensitivity, ... 1185
specificity, ... 1185
Western blot assay
sensitivity, ... 1185
specificity, ... 1185
Human T-cell lymphotropic virus type II immunoassay
Sweden, ... 845
sensitivity, ... 845
specificity, ... 845
transfusion complication, ... 845
West Africa, ... 845
sensitivity, ... 845
specificity, ... 845
Human-peripheral blood lymphocyte-severe combined immune-deficient mice, CD154
alloimmunization, ... 818
HLA-specific alloantibody, ... 818
IgG, ... 818
T cell, ... 818
Hunter's syndrome, ... 343
Hydroxyethyl starch
endothelial cell monolayer, ... 289
umbilical endothelial cell, ... 289
white cell, ... 289
Hyperglycemia, ... 998
Hypocalcemia, ... 998
Hypotensive reaction
angiotensin-converting enzyme, ... 1084
bedside white cell-reduction filter, ... 1084
bradykinin, ... 107(L)
enalaprilat, ... 1084
transfusion complication, ... 1084
Hypotonic shock response, white cell reduction, ... 724
Hysterectomy
autologous blood donation, ... 801
transfusion rate, ... 801

I

I antigen, ... 1060
cord blood, ... 1060
fetal blood, ... 1060
Iatrogenic anemia, autologous blood donation, ... 801
Iduronate-2-sulfatase, ... 343
IgA deficiency, autologous bone marrow transplant, ... 457
circulating anti-IgA, ... 457
cryopreserved autologous plateletpheresis components, ... 457
manually allogeneic plateletpheresis components, ... 457
washed red cells, ... 457
IgG, ... 818
flow cytometry, ... 756
2-mercaptoethanol, ... 756
pregnancy, ... 379
subclass concentration, enzyme-linked immunosorbent assay, ... 515
IgG antibody, ... 1065
albumin, ... 682
EXCORIM, ... 682
immunoadsorption system, ... 682
plasma exchange, ... 682
staphylococcal protein A immunoadsorption system, ... 682
IgG anti-D
enzyme-linked immunosorbent assay, ... 515
hemagglutination, ... 515
IgG1 antibody, IgG3 antibody, synergistic effects of blending, ... 1005
IgG1 anti-D, ... 1005
IgG3 antibody, IgG1 antibody, synergistic effects of blending, ... 1005
IgG3 anti-D, ... 1005
IgM
flow cytometry, ... 756
2-mercaptoethanol, ... 756
Immune complex-mediated hemolysis, epitope responsible, ... 306
Immune hemolysis
indirect antiglobulin crossmatch, ... 295
pretransfusion direct antiglobulin test, ... 295
Immune hemolytic anemia
cefotaxime, ... 1239
cefotetan, ... 1239
cefoxitin, ... 1239
ceftizoxime, ... 838
ceftriaxone, ... 1239
cephalosporin, serology of antibodies, ... 1239
drug-induced, ... 1239
immunohematology, ... 1239
transfusion complication, ... 838
Immune tolerance, hemophiliac, ... 1034(L)
Immunoadsorption system
acetylcholine receptor, ... 682
autoimmune disorder, ... 682
IgG antibody, ... 682
myasthenia gravis, ... 682
Immunoblotting, ... 1104
Immunofluorescence assay, ... 1104
Immunoglobulin
antiglobulin test, ... 537(L)
enzyme-linked immunosorbent assay, ... 515
ethanol precipitation, ... 249
hepatitis B virus, ... 1160
hepatitis C virus, ... 249, 1160
hepatitis G virus, manufactured in Europe, ... 428(L)
hepatitis G virus E2 antigen, ... 1271(L)
human immunodeficiency virus, ... 1160
pasteurization, ... 249
polyethylene glycol, ... 537(L)
virus transmission, ... 1160
Immunoglobulin isotype identification
flow cytometry, ... 756
2-mercaptoethanol, ... 756
Immunohematology, ... 1045
807 C/T polymorphism, ... 372
ABO chimera, ... 1247
ABO grouping, ... 300
ABO mosaicism, ... 1247
agglutination index, ... 1051
anti-G, ... 531
biotin-labeled red cell, ... 1065
CD34+ cell, ... 864
international study, ... 856
standardization of CD34+ cell enumeration, ... 856
CD36 deficiency, ... 873
ceftizoxime, ... 306
cephalosporin, ... 1239
complement receptor 1 red cell expression, ... 751
D antigen, ... 17
male fetus, ... 169
D monoclonal antibody, ... 1005
D typing, ... 300
detecting alloantibodies underlying warm autoantibodies, ... 11
FcγRIIIB polymorphism, ... 593
α (1,2)-fucosyltransferase gene mutation, ... 1013
hematologic disease, ... 763
HPA-1a phenotyping, ... 781
HPA-5 polymorphism, ... 372
HPA-5b antibody, ... 379
immune hemolytic anemia, ... 1239
immunoglobulin isotype identification, ... 756
In(Lu) gene, ... 751
isolating high-affinity Fab fragments, ... 364
lectin, ... 1060
neutropenia, ... 527

NOR polyagglutination, ... 32
oncologic disease, ... 763
partial D phenotype DBT, ... 1259
platelet glycoprotein Ia molecule, ... 372
private HLA class I epitope antibody, ... 772
public HLA class I epitope antibody, ... 772
red cell antibody screening of pregnant women, ... 26
red cell antigen, ... 163
RHCE genotyping, ... 852
RHD genotyping, ... 852
serologic reactivity after 37BC incubation, ... 295
St^a glycophorin, ... 32
ultraviolet and visible light spectrophotometry, ... 1051
volumetric capillary cytometry, ... 864
Immunomodulation, white cell reduction, ... 665(E)
Immunosilent AIDS
acute retroviral syndrome, distinguishing, ... 383
anti-human immunodeficiency virus enzyme immunoassay, ... 383
blood donor, ... 383
CD4+, ... 383
human immunodeficiency virus p24 antigen assay, ... 383
human immunodeficiency virus polymerase chain reaction, ... 383
Western blot, ... 383
Imugard filter, temperature, ... 265
Indirect antiglobulin test
cephalosporin, ... 1239
immune hemolysis, ... 295
transfusion reaction, ... 295
Indirect immunofluorescence assay, granylocyte antibody, ... 983
I-negative adult red cell, *Aplysia* gonad lectin, ... 1060
Infant. *See also* Neonate
limited-donor program, ... 938
Inflammatory mediator, ... 271
In-line white cell-reduction system, ... 572, 960
In(Lu) gene
immunohematology, ... 751
Knops system antigen, ... 751
Lu(a–b–) phenotype, ... 751
Lu^b, ... 751
Inner-city emergency department
human T-cell lymphotropic virus type I, ... 1185
human T-cell lymphotropic virus type II, ... 1185
Instance of the Fingerpost, book review, ... 339
Interferon gamma
red cell, ... 718
white cell reduction, ... 718
Interleukin, ... 179
Interleukin-1β, ... 899
nonhemolytic transfusion reaction, ... 1179
Interleukin-2
red cell, ... 718
white cell reduction, ... 718
interleukin-3, ... 321
Interleukin-6, ... 271, 899
febrile nonhemolytic transfusion reaction, ... 231
nonhemolytic transfusion reaction, ... 1179
Interleukin-8, ... 271
aminomethyltrimethyl psoralen, ... 239
gamma-radiation, ... 239
8-methoxypsoralen, ... 239
nonhemolytic transfusion reaction, ... 1179
psoralen, ... 239
S-59, ... 239
ultraviolet A light, ... 239
interleukin-11, ... 321
International reference preparation coded 68/419, enzyme-linked immunosorbent assay, ... 515
International Society for Hematotherapy and Graft Engineering (ISHAGE) guidelines, ... 1220
Intraoperative blood salvage, ... 910
irradiation, ... 608
tumor cell, ... 608
Intravenous drug user, ... 83
Intravenous immunoglobulin, ... 83
Investigational New Drug license, ... 341(E)
Food and Drug Administration
donor recruitment, ... 357
reporting of positive infectious disease, ... 357
sample tracking, ... 357
transplant recipient outcome data collection, ... 357
use of unlicensed materials, ... 357
umbilical cord blood bank, ... 357
I-positive adult red cell, *Aplysia* gonad lectin, ... 1060
Iron
autologous blood donation
allogeneic blood transfusion, ... 465
elective surgery, ... 465
hemoglobin, ... 465
intravenous iron, ... 465
number of autologous units donated, ... 465
oral iron, ... 465
randomized controlled study, ... 465
red cell production, ... 465
therapeutic phlebotomy, ... 651
Iron-deficiency anemia, two-unit red cell apheresis, ... 218
Iron-depletion therapy, ... 578
Irradiation
intraoperative blood salvage, ... 608
tumor cell, ... 608

J

Japan
chemiluminescent immunoassay, ... 660(L)
donor screening, ... 1104
hepatitis B virus, ... 660(L)
human T-cell lymphotropic virus type I, ... 1104
partial D phenotype DBT, ... 1259
inheritance, ... 1259
molecular basis, ... 1259
RANTES, ... 498
transforming growth factor-β, ... 498
TT virus, ... 522
Jk agglutinin, ... 295
Jk^a antibody, transfusion reaction, ... 1097

K

K agglutinin, ... 295
K562 cell, ... 17
D_{mut} construct, ... 17
Knops system antigen, *In(Lu)* gene, ... 751

L

Lactate
storage, ... 492
temperature, ... 492
Lactate dehydrogenase
anti-Tc^a, ... 948
Cromer system antibody, ... 948
Lan expression, variation, ... 109(L)
Large-volume leukapheresis
breast cancer, ... 1120
CD34+ cell, ... 1120
colony-forming units/196granulocyte-macrophage, ... 1120
engraftment, ... 1120
non-Hodgkin's lymphoma, ... 1120
normal-volume leukapheresis, prospective randomized sequential crossover trial, ... 1120
progenitor cell, ... 1120
Latin America, Chagas' disease, ... 711
Le(a+b+), Thai population, ... 1013
Le(a+b–), Thai population, ... 1013
Lectin
antigen recognition, ... 1060
blood group typing, ... 1060
immunohematology, ... 1060
Leishmaniasis, recombinant peptide antigen line immunoassay, ... 711
Leucoflex filter, temperature, ... 265
Leukapheresis. *See also* Normal-volume leukapheresis

CD34+ cell, ... 403
polymorphonuclear cell, ... 403
Leukemia. *See also* Specific type
pooled random-donor platelet, ... 925
single-donor platelet, ... 925
Lewis histo-blood group system, ... 1013
Light-chain shuffling, Fab fragment, ... 364
Limited-donor program
infant, ... 938
neonatal red cell transfusions, cost-effectiveness, ... 938
very-low-birthweight infant, ... 938
Line immunoassay, Chagas' disease, ... 711
Lipid peroxidation product, thalassemic patient, ... 333(L)
Lipopolysaccharide
elutriation, ... 975
monocyte, ... 975
thrombin, ... 975
tissue factor, ... 975
tissue factor pathway inhibitor, ... 975
Liquid-preserved platelet
activated glycoproteinIIb/IIIa, ... 880
adhesive surface receptors, ... 880
factor V, ... 880
glycoprotein Ib, ... 880
membrane procoagulant activity, ... 880
p-selectin, ... 880
Liver disease coagulopathy
fresh-frozen plasma, ... 1227
solvent/detergent-treated fresh-frozen plasma, ... 1227
Liver transplantation
fresh-frozen plasma, ... 1227
solvent/detergent-treated fresh-frozen plasma, ... 1227
clotting factor, ... 1227
hepatitis A virus, ... 1227
hepatitis B virus, ... 1227
hepatitis C virus, ... 1227
human immunodeficiency virus, ... 1227
human parvovirus B19, ... 1227
partial thromboplastin time, ... 1227
Long-term culture, dextran sedimentation, ... 1212
Long-term culture-initiating cell, dextran sedimentation, ... 1212
LRF6 white cell reduction filter, ... 74
filtration flow rate, ... 74
platelet loss, ... 74
platelet storage quality, ... 74
white cell count, ... 74
LRFXL white cell reduction filter, ... 74
filtration flow rate, ... 74
platelet loss, ... 74
platelet storage quality, ... 74
white cell count, ... 74
LS2N, ... 343
Lu(a–b–) phenotype, *In(Lu)* gene, ... 751
Lu^{b}, *In(Lu)* gene, ... 751
LW(a+) red cell, ... 163
Lymphocyte
aluminum phthalocyanine tetrasulfonate, ... 599
AMICUS cell separator, ... 420
annexin V, ... 599
apoptosis induction, ... 599
citrate, ... 420
MCS 3p cell separator, ... 420
phthalocyanine, ... 599
prodidium iodide, ... 599
red cell, ... 718
white cell reduction, ... 718
Lymphocyte cytotoxicity test, ... 944
Lymphocyte gene therapy, ... 343
Lymphocyte (K-cell) antibody-dependent cell-mediated cytotoxicity, D monoclonal antibody, ... 1005
Lymphopenia
red cell, ... 718
white cell reduction, ... 718
Lysosomal integral membrane protein, platelet concentrate preparation, ... 951

M

Macrophage inflammatory protein 1alpha, nonhemolytic transfusion reaction, ... 1179
Macular hole, platelet concentrate
platelet-derived growth factor, ... 144
plateletpheresis, ... 144
preparation of autologous platelet, ... 144
transforming growth factor-β, ... 144
visual acuity, ... 144
whole-blood preparation, ... 144
wound healing, ... 144
Major ABO incompatibility, ABO-incompatible bone marrow, ... 1273(L)
Mannitol, ... 998
MaternalCneonatal donor pair, ... 415
deferral factors, ... 415
MCS+, ... 572
granulocyte activation, ... 735
platelet activation, ... 735
plateletCgranulocyte heterotypic aggregate formation, ... 735
p-selectin, ... 735
white cell reduction, ... 572
MCS 3p cell separator
D-dimer, ... 420
lymphocyte, ... 420
monocyte, ... 420
mononuclear cell, ... 420
plasminogen activator inhibitor, ... 420
plasmin-plasmin inhibitor complex, ... 420
platelet-neutrophil aggregate, ... 420
prothrombin fragment, ... 420
MCS+ apheresis unit, ... 218
MCS+ LN9000 apheresis system, white cell reduction, continuous filtration, ... 74
Megakaryocyte–colony-forming cell, ... 321
Megakaryocytopoiesis, ... 899
2-Mercaptoethanol
IgG, ... 756
IgM, ... 756
immunoglobulin isotype identification, ... 756
Metamizole, neutropenia, ... 527
granulocyte agglutination test, ... 527
monoclonal antibody-specific immobilization of granulocyte antigens assay, ... 527
8-Methoxypsoralen
febrile nonhemolytic transfusion reaction, ... 239
interleukin ... 8, 239
Methylene blue
factor VIII/von Willebrand factor molecular complex, ... 748
factor XIII, ... 748
fibrinogen, ... 748
plasma, ... 63
CD62 expression, ... 63
glucose, ... 63
hemoglobin, ... 63
hemolysis, ... 63
lactate, ... 63
lactate dehydrogenase, ... 63
osmotic recoveries, ... 63
pH, ... 63
platelet morphology scores, ... 63
platelet numbers, ... 63
potassium, ... 63
red cell antigen stability, ... 63
von Willebrand disease, ... 748
MH04 monoclonal anti-A agglutinated red cell, ... 163
Microlymphocytotoxicity, computerized analysis, ... 772
Microtube column agglutination system
red cell alloantibody, system comparison, ... 1045
tube low-ionic-strength solution indirect antiglobulin test, compared, ... 1045

Microvolume fluorimetry method, CD34+ cell, ... 856
Minor ABO incompatibility
  ABO-incompatible bone marrow, ... 1273(L)
  allogeneic peripheral blood progenitor cell transplantation, delayed massive immune hemolysis, ... 824
  bone marrow transplantation, ... 824
  transplantation, ... 824
Mixed lymphocyte culture
  buffy coat-depleted red cell, ... 1089
  white cell filtered red cell, ... 1089
MNS blood group system antigen, ... 364
Monoclonal antibody-specific immobilization of platelet antigen, HPA-5b antibody, ... 379
Monoclonal antigen immobilization of granulocyte antigen, ... 944
Monocyte
  aluminum phthalocyanine tetrasulfonate, ... 599
  AMICUS cell separator, ... 420
  annexin V, ... 599
  apoptosis induction, ... 599
  citrate, ... 420
  counterflow centrifugal elutriation, ... 975
  lipopolysaccharide, ... 975
  MCS 3p cell separator, ... 420
  phthalocyanine, ... 599
  prodidium iodide, ... 599
  thrombin, ... 975
Monocyte antibody-dependent cell-mediated cytotoxicity, D monoclonal antibody, ... 1005
Monocyte CD36, ... 873
Monocyte chemiluminescence, D monoclonal antibody, ... 1005
Monocyte monolayer assay
  anti-Tc^{a} 948
  Cromer system antibody, ... 948
Monocytic cell line THP-1, ... 975
Mononuclear cell, ... 48
  AMICUS cell separator, ... 420
  CD34+ cell, ... 403
  citrate, ... 420
  dextran sedimentation, ... 1212
  MCS 3p cell separator, ... 420
  polymorphonuclear cell, ... 403
  Spectra apheresis system, ... 661(L)
Moroccan family, partial D phenotype DBT, *RHD-CE-D* gene, ... 1259
Mouse model, ... 818
Mpl ligand, ... 258, 899
  platelet growth factor, ... 321
Mucopolysaccharidosis type II, ... 343
Multicomponent apheresis
  plasma, ... 565
  red cell, ... 565
  in vivo red cell recovery, ... 565
  white cell-reduced, ... 565
Multiple mouse hybridoma antibody, ... 364
Multiple-organ failure, ... 179
Muscular dystrophy
  anti-c, ... 763
  anti-E, ... 763
  antigen matching, ... 763
  anti-K, ... 763
  Rh system antibody, ... 763
Myasthenia gravis, ... 682
  albumin, ... 682
  EXCORIM, ... 682
  immunoadsorption system, ... 682
  plasma exchange, ... 682
  staphylococcal protein A immunoadsorption system, ... 682
Myelodysplastic syndrome, ... 179, 1247
Myeloproliferative syndrome
  anti-c, ... 763
  anti-E, ... 763
  antigen matching, ... 763
  anti-K, ... 763
  Rh system antibody, ... 763

N
N92 anti-N IgG monoclonal antibody, ... 364
N92 Fab fragment, ... 364
NA1
  Denmark, ... 593
  FcγRIIIB polymorphism, ... 593
NA2
  Denmark, ... 593
  FcγRIIIB polymorphism, ... 593
  polymerase chain reaction with sequence-specific primers, ... 593
Natural killer cell
  red cell, ... 718
  white cell reduction, ... 718
Nausea, therapeutic apheresis, ... 282
Neonatal alloimmune thrombocytopenia, HPA-5b antibody
  IgG titer, ... 379
  light-chain phenotype, ... 379
  subclass, ... 379
Neonate
  cytomegalovirus, ... 201
  red cell transfusions limited-donor program, cost-effectiveness, ... 938
Nested polymerase chain reaction, ... 1104
Neutropenia
  cefotaxime, ... 527
    granulocyte agglutination test, ... 527
    monoclonal antibody-specific immobilization of granulocyte antigens assay, ... 527
  drug-dependent antibodies, ... 527
  granulocyte–colony-stimulating factor, ... 527
  metamizole, ... 527
    granulocyte agglutination test, ... 527
    monoclonal antibody-specific immobilization of granulocyte antigens assay, ... 527
Neutrophil
  AMICUS cell separator, ... 420
  granulocyte–colony-stimulating factor, ... 1136
New variant Creutzfeldt-Jacob disease, ... 919(E)
  white cell reduction, ... 919(E)
Nitric oxide
  biotinylated platelet, ... 506
  platelet activation, ... 506
  plateletpheresis, ... 506
NNA7 Fab fragment, ... 364
Non-A to -G hepatitis
  alanine aminotransferase, ... 522
  TT virus, ... 522
Nonhemolytic transfusion reaction, ... 498
  bedside filtration, ... 1179
  chemokine RANTES, ... 1179
  interleukin 1β, ... 1179
  interleukin 6, 1179
  interleukin 8, 1179
  macrophage inflammatory protein 1α, ... 1179
  platelet-derived mediator, ... 1179
  prestorage white cell filtration, ... 1179
  RANTES, ... 1179
  tumor necrosis factor α, ... 1179
  white cell-derived inflammatory cytokine, ... 1179
Non-Hodgkin's lymphoma, ... 442
  anti-c, ... 763
  anti-E, ... 763
  antigen matching, ... 763
  anti-K, ... 763
  GB virus type C, ... 212
    alanine aminotransferase, ... 212
    anti-E2, ... 212
  hepatitis C virus, ... 212
  large-volume leukapheresis, ... 1120
  normal-volume leukapheresis, ... 1120
  pooled random-donor platelet, ... 925
  Rh system antibody, ... 763

single-donor platelet, ... 925
NOR polyagglutination
α-galactosidase, ... 32
glycolipid, ... 32
glycophorin, ... 32
Griffonia simplicifolia IB4 lectin, ... 32
immunohematology, ... 32
Ricinus communis agglutinin I, ... 32
Normal-volume leukapheresis
breast cancer, ... 1120
CD34+ cell, ... 1120
colony-forming units/196granulocyte-macrophage, ... 1120
engraftment, ... 1120
large-volume leukapheresis, prospective randomized sequential crossover trial, ... 1120
non-Hodgkin's lymphoma, ... 1120
progenitor cell, ... 1120
Nucleated cell, dextran sedimentation, ... 1212
Nucleic acid amplification testing
blood collection, ... 1141
detection threshold, ... 1141
human immunodeficiency virus type 1, 1141
maximum yield, ... 1141
pool size, ... 1141
window period, ... 1141
Nucleic acid testing
hepatitis C virus, Food and Drug Administration workshop, ... 912(L)
human immunodeficiency virus, seronegative window, ... 688

O

O blood group, agglutination index, ... 1051
O_h red cell, *Aplysia* gonad lectin, ... 1060
Oligonucleotide probe, ... 1111
Ortho BioVue
antibody reactivity, ... 1045
anti-Le^a antibody, ... 1045
anti-Le^b antibody, ... 1045
anti-M antibody, ... 1045
anti-N antibody, ... 1045
anti-P_1 antibody, ... 1045
tube low-ionic-strength solution indirect antiglobulin test, compared, ... 1045
Orthopedic surgery
buffy coat-depleted blood component, ... 625
recombinant human erythropoietin, ... 933
red cell, ... 718
T-cell-mediated immunity, ... 1089
white cell reduction, ... 718
Osteoblastic activity, granulocyte–colony-stimulating factor, ... 410
Osteocalcin, ... 410
Osteomyelitis, allogeneic blood transfusion, ... 694
Oxime-type cephalosporin, ... 306

P

P system antigen, *Aplysia* gonad lectin, ... 1060
p19 reactivity, ... 1145
p24 antigen, ... 688
p24 antigen test, ... 1141
Packed red cell unit, automated collection system, ... 460
Parenteral transmission
GB virus type C/hepatitis G virus anti-E2, ... 83
GB virus type C/hepatitis G virus RNA, ... 83
Parity, HLA sensitization, ... 103
Paroxysmal nocturnal hemoglobinuria, granulocyte-agglutinating antibody
hemolysis, ... 944
renal failure, ... 944
transfusion-related acute lung injury, ... 944
Partial D phenotype DBT
immunohematology, ... 1259
Japanese family, ... 1259
inheritance, ... 1259
molecular basis, ... 1259
Moroccan family, *RHD-CE-D* gene, ... 1259
Partial thromboplastin time, ... 1227
Pasteurization
bovine viral diarrhea virus, ... 249
encephalomyocarditis virus, ... 249
human immunodeficiency virus, ... 249
immune globulin, ... 249
pseudorabies virus, ... 249
Sindbis virus, ... 249
vaccinia virus, ... 249
vesicular stomatitis virus, ... 249
pBabe puromycin retroviral vector, ... 17
Penicillin, ... 306
hemolytic anemia, ... 306
Percent platelet recovery, platelet transfusion
potential for data distortion, ... 586
regression analysis, ... 586
Perioperative hemodilution, ... 1027
Peripheral blood
DNA, polymerase chain reaction-restriction fragment length polymorphism, ... 1247
volumetric capillary cytometry, ... 864
Peripheral blood lymphocyte
cell yield, ... 343
expanded, ... 343
hollow-fiber bioreactor, ... 343
transduced, ... 343
Peripheral blood progenitor cell, ... 1120
apheresis device, ... 1200
automated leukapheresis system, ... 1200
collection, ... 442
in children, ... 334(L)
filgrastim, safety, ... 555
granulocyte–colony-stimulating factor, ... 1136, 1207
CD34+ cell, ... 1207
number of leukapheresis procedures, ... 1207
optimal dose, ... 1207
retrospective study, ... 1207
kinetics during apheresis, ... 403
large-volume leukapheresis, ... 1120
normal-volume leukapheresis, ... 1120
optimal growth factor dosing, ... 39
progenitor assay, ... 451
Peripheral blood progenitor cell apheresis product, ... 1220
pH, white cell reduction, ... 724
Photodynamic sterilization, red cell, ... 599
contaminating white cells, ... 599
mechanism of cell death, ... 599
viability, ... 599
Photoinactivation, ... 63
Phthalocyanine
granulocyte, ... 599
lymphocyte, ... 599
monocyte, ... 599
white cell, ... 599
Phycoerythyrin, ... 1220
Phytohemagglutinin
buffy coat-depleted red cell, ... 1089
white cell filtered red cell, ... 1089
Plant lectin, *Aplysia* gonad lectin, ... 1060
Plasma. *See also* Fresh-frozen plasma
cost-effectiveness, ... 479
methylene blue, ... 63
CD62 expression, ... 63
glucose, ... 63
hemoglobin, ... 63
hemolysis, ... 63
lactate, ... 63
lactate dehydrogenase, ... 63
osmotic recoveries, ... 63
pH, ... 63
platelet morphology scores, ... 63
platelet numbers, ... 63

potassium, ... 63
red cell antigen stability, ... 63
multicomponent apheresis, ... 565
Plasma depletion
febrile nonhemolytic transfusion reaction, ... 231
randomized controlled trial, ... 231
Plasma derivative
hepatitis B virus, ... 1160
hepatitis C virus, ... 1160
human immunodeficiency virus type I, ... 1160
virus transmission, ... 1160
Plasma enzyme, white cell reduction, ... 724
Plasma exchange
acetylcholine receptor, ... 682
autoimmune disorder, ... 682
IgG antibody, ... 682
myasthenia gravis, ... 682
selective therapeutic extraction of plasma constituents, ... 671(E)
Plasma fibrinogen, ... 277
Plasma fraction, transmissible spongiform encephalopathy, ... 1169
high-speed centrifugation, ... 1169
infectivity levels, ... 1169
intracerebral route, ... 1169
intravenous route, ... 1169
white cell-reduction filtration, ... 1169
Plasma incompatibility, ABO-incompatible bone marrow, ... 1273(L)
Plasma-derived polyclonal anti-D, ... 1005
Plasmapheresis program
reasons for donor cessation, ... 900
remuneration, importance, ... 900
Plasminogen activator inhibitor
AMICUS cell separator, ... 420
citrate, ... 420
MCS 3p cell separator, ... 420
Plasmin-plasmin inhibitor complex
AMICUS cell separator, ... 420
citrate, ... 420
MCS 3p cell separator, ... 420
Platelet. *See also* Fresh platelet; Liquid-preserved platelet; Pooled random-donor platelet
AMICUS separator, ... 895
baboon model, ... 880
biology of platelet production, ... 321
dimethyl sulfoxide, ... 616
ethylene glycol, ... 616
febrile nonhemolytic transfusion reaction, ... 231
fluorescein, ... 616
ADP, ... 616
p-selectin, ... 616
ristocetin, ... 616
thrombin, ... 616
glucose, ... 616
glycerol, ... 616
hematopoietic growth factor, ... 321
hemostasis, ... 967
hemostatic properties, ... 967
L-proline, ... 616
1,2-propanediol, ... 616
Spectra LRS separator, ... 895
sucrose, ... 616
thrombosis, ... 967
transfusion cost, ... 321
trehalose, ... 616
uses, ... 321
Platelet activation, ... 506
filtration, ... 498
gamma radiation, ... 498
MCS+, ... 735
nitric oxide, ... 506
plateletpheresis, ... 735
plateletpheresis instrument, ... 735
sodium nitroprusside, ... 506
storage, ... 498
platelet membrane integrity, ... 616
temperature, platelet membrane integrity, ... 616
white cell reduction, ... 724
Platelet aggregate, white cell reduction, ... 724
Platelet antigen
apheresis, ... 742
cell separator, ... 742
storage, ... 742
Platelet cell membrane, lipid-phase transition, ... 616
Platelet component
filtration, ... 498
gamma radiation, ... 498
storage, ... 498
Platelet concentrate
buffy coat method, ... 951
clump formation, ... 913(L)
coagulation factor Va, ... 951
cytokine
photochemical treatment, ... 239
psoralen plus ultraviolet A light, ... 239
fibrinogen, ... 951
fibronectin, ... 951
lysosomal integral membrane protein, ... 951
macular hole
platelet-derived growth factor, ... 144
plateletpheresis, ... 144
preparation of autologous platelet, ... 144
transforming growth factor-β, ... 144
visual acuity, ... 144
whole-blood preparation, ... 144
wound healing, ... 144
optimal platelet dosing, ... 431(L)
platelet glycoprotein, ... 951
platelet-rich plasma method, ... 951
p-selectin, ... 951
second-messenger effector, quality assessment, ... 135
storage, ... 135
activation-dependent antigens, ... 951
platelet adhesive and cohesive functions, ... 951
procoagulant activity, ... 951
sterility testing false-positive and false-negative results, ... 539(L)
ThromboSol, ... 135
von Willebrand factor, ... 951
white cell reduction, ... 724
Platelet glycoprotein, platelet concentrate preparation, ... 951
Platelet glycoprotein Ia molecule
807 C/T polymorphism, ... 372
HPA-5 polymorphism, ... 372
Platelet growth factor, ... 321
adverse effects, ... 321
biologic effects, ... 321
human clinical studies, ... 321
Mpl ligand, ... 321
transfusion medicine impact, ... 321
Platelet membrane CD36, ... 873
Platelet storage lesion, ... 135
recombinant human megakaryocyte growth and development factor, ... 258
storage, ... 258
Platelet substitute, ... 1027
Platelet transfusion
corrected count increment
potential for data distortion, ... 586
regression analysis, ... 586
dose-response relationship, ... 674
prospective randomized double-blind multiple-crossover study, ... 674
hematopoietic progenitor cell transplant, ... 674
percent platelet recovery
potential for data distortion, ... 586
regression analysis, ... 586

Platelet–granulocyte heterotypic aggregate formation
MCS+, 735
plateletpheresis instrument, 735
plateletpheresis, 735
Platelet-derived growth factor, 144
Platelet-derived mediator, nonhemolytic transfusion reaction, 1179
Platelet-derived soluble plasminogen activator inhibitor type 1, 1078
Platelet-neutrophil aggregate
AMICUS cell separator, 420
citrate, 420
MCS 3p cell separator, 420
Plateletpheresis, 960
blood collection, 895
donor's health, 420
efficiency, 895
hemoglobin, 790(L)
HLA sensitization, 103
nitric oxide, 506
platelet activation, 735
platelet–granulocyte heterotypic aggregate, 735
p-selectin
plasma-soluble, 735
platelet surface, 735
safety issues, 420
serum thrombopoiesis growth factor, 429(L)
white cell reduction, cell separators compared, 572
Plateletpheresis instrument
granulocyte activation, 735
platelet activation, 735
platelet–granulocyte heterotypic aggregate formation, 735
p-selectin, 735
Platelet-rich plasma, soluble vascular endothelial growth factor, 1078
Pneumonia, allogeneic blood transfusion, 694
Polyclonal anti-A, 163
Polyethylene glycol, 258
adsorption, 11
antibody reactivity, 1272(L)
antiglobulin test, 537(L)
immunoglobulin, 537(L)
potentiator, 1239
technique
antibody detection, 1097
transfusion reaction, 1097
Polymerase chain reaction, 852
human T-cell lymphotropic virus type I
sensitivity, 1185
specificity, 1185
human T-cell lymphotropic virus type II
sensitivity, 1185
specificity, 1185
human T-lymphotropic virus type I *tax* sequence, 904
analytical sensitivity, 904
TT virus, 522
Polymerase chain reaction with sequence-specific primers
NA2, 593
SH, 593
Polymorphonuclear leukocyte, 289
leukapheresis, 403
mononuclear cell, 403
white cell, 403
Pooled random-donor platelet
acute myelogenous leukemia, 925
breast cancer, 925
chronic myelogenous leukemia, 925
coronary artery bypass grafting, 925
decision analysis model, 925
hematopoietic progenitor cell transplantation, 925
hepatitis B virus, 925
hepatitis C virus, 925
human immunodeficiency virus, 925
human T-cell lymphotropic virus type I, 925
human T-cell lymphotropic virus type I-associated myelopathy, 925
leukemia, 925
non-Hodgkin's lymphoma, 925
sensitivity analysis, 925
Postage stamps, of transfusion medicine, 534
Postcollection filtration, white cell reduction, 74
Postoperative infection, buffy coat-depleted blood component, 625
Postoperative pneumonia, coronary artery bypass graft, red cell storage time, 701
Poststorage white cell reduction, febrile nonhemolytic transfusion reaction, 231
Potassium, 128
Pregnancy, 17
ABO incompatibility
direct antiglobulin test, 26
solid-phase screening test, 26
anti-G, 531
anti-Hr_0, 1151
D-- phenotype, 1151
HLA sensitization, 103
IgG subclass, 379
pregnancy-induced anti-HPA-5b, 379
red cell antibody, 26
solid-phase screening test, 26
transfusion-related acute lung injury, 103
Preoperative autologous blood donation, 910
anemia, 174
elderly patient
accessible superficial vein, 174
allogeneic blood, 174
anemia, 174
cardiovascular complication, 174
incidence of complications, 174
vasovagal reaction, 174
Prestorage white cell filtration
in-line filtration, 107(L)
nonhemolytic transfusion reaction, 1179
white cell-poor platelet preparation, 1179
Preterm infant, anemia, 149, 156
Pretransfusion direct antiglobulin test
immune hemolysis, 295
transfusion reaction, 295
Private HLA class I epitope antibody, immunohematology, 772
ProCOUNT kit, CD34+ cell, 1220
ProCOUNT software, CD34+ cell, 1220
Prodidium iodide
granulocyte, 599
lymphocyte, 599
monocyte, 599
Progenitor assay
assay consistency, 451
assay steps, 451
ficoll, 451
granulocyte–colony-stimulating factor, 451
peripheral blood progenitor cell, 451
variability, 451
L-Proline, platelet, 616
1,2-Propanediol, platelet, 616
Protein C, fresh-frozen plasma, 488
Protein S, fresh-frozen plasma, 488
Proteinase-resistant protein, 1169
Prothrombin, dilutional coagulopathy, tests compared, 56
Prothrombin fragment
AMICUS cell separator, 420
citrate, 420
MCS 3p cell separator, 420
Prothrombin reagent, differences, 56
Prothrombin splits product, citrate, 1266
P-selectin
cryopreserved platelet, 880
fresh platelet, 880
liquid-preserved platelet, 880

MCS+, 735
platelet concentrate preparation, 951
plateletpheresis
plasma-soluble, 735
platelet surface, 735
plateletpheresis instrument, 735
Pseudomonas aeruginosa (galactophilic) lectin, *Aplysia* gonad lectin, 1060
Pseudorabies virus
ethanol precipitation, 249
pasteurization, 249
Psoralen
febrile nonhemolytic transfusion reaction, 239
interleukin, 8, 239
Psoralen photochemistry, 63
Public HLA class I epitope antibody, immunohematology, 772
Pulse, blood donor, 316
Puromycin-resistent K562 clone, 17

Q

Quality improvement, data acquisition, 351

R

RANTES
blood component, 498
filtration, 498
gamma radiation, 498
Japan, 498
nonhemolytic transfusion reaction, 1179
storage, 498
Rapid plasma reagin test, syphilis, 206
Recombinant envelope protein, 21, 1185
Recombinant human erythropoietin
administration, 933
autologous blood donation, 933
cost-effectiveness, 933
decision tree analysis, 933
France, 933
orthopedic surgery, 933
Recombinant human megakaryocyte growth and development factor apheresis platelet, 258
platelet storage lesion, 258
Recombinant IgG1-based assay, HPA-1a phenotyping, 781
Recombinant immunoblot assay, hepatitis C virus
anti-NS5, 790(L)
GB virus type C, 790(L)
hepatitis G virus, 790(L)
Recombinant peptide antigen line immunoassay
Chagas' disease, 711
leishmaniasis, 711
Recordkeeping
lookback and traceback procedures, 351
quality, 351
Red cell
^{51}Cr, 149
measuring circulating red cell volume, 149
measuring red cell survival, 156
additive solution, 5, 991
biotinylation, 149
antibodies, 1065
antiglobulin technique, 1065
circulating kinetics, 1065
dithiothreitol, 1065
group O red cell, 1065
IgG antibodies, 1065
immunogenicity, 1065
immunohematology, 1065
measuring circulating red cell volume, 149
measuring red cell survival, 156
neoantigens, 1065
red cell volume, 1065
blood component, 991
bone marrow, 1212
coronary artery bypass graft, 701
number of units, 701
storage time, 701
cytokine, 718
dextran sedimentation, 1212
erythropoietin, 392
hematocrit, 392
interferon gamma, 718
interleukin-2, 718
lymphocyte, 718
lymphopenia, 718
multicomponent apheresis, 565
natural killer cell, 718
orthopedic surgery, 718
outcome study design, 657(L)
photodynamic sterilization, 599
contaminating white cells, 599
mechanism of cell death, 599
viability, 599
prospective randomized design study, 657(L)
storage, 128
dextran-containing buffer, 277
immunomodulation, 701
postoperative pneumonia, 701
red cell aggregability, 277
red cell alteration, 277
two-unit red cell apheresis, 218
Red cell 2,3 DPG
storage, 492
temperature, 492
Red cell agglutination, new detection methods, 1037(E)
Red cell alloantibody, 1045
microtube column agglutination system, system comparison, 1045
Red cell antibody
pregnancy, 26
solid-phase screening test, 26
semiautomated solid-phase method of screening, 26
Red cell antigen, biotin, 163
antigen-negative cells, 163
antigen-positive cell, 163
BIRMA-1 monoclonal anti-A, 163
Di(b+) red cell, 163
hemagglutination assay, 163
LW(a+) red cell, 163
MH04 monoclonal anti-A agglutinated red cell, 163
polyclonal anti-A, 163
Red cell ATP, 128
Red cell substitute
anemia, 396
mathematical modeling, 396
Renal failure, 944
Respiratory distress, therapeutic apheresis, 282
Restriction fragment length polymorphism analysis, hepatitis C virus genotype, 5' noncoding region, 1194
Reticulocyte, 271
Retroviral vector, 343
Retrovirus, gene transfer, 795(E)
Reverse transcriptase polymerase chain reaction
bcr/abl translocation, 387
hepatitis B virus, 1111
hepatitis C virus, 1111
hepatitis C virus RNA, 1111
Rh agglutinin, 295
RH gene
exon-specific polymerase chain reaction, 1259
Southern blot analysis, 1259
Rh hemolytic disease of newborn, 1005
Rh system antibody
acute lymphoblastic leukemia, 763
acute myeloid leukemia, 763
chronic lymphocytic leukemia, 763
muscular dystrophy, 763
myeloproliferative syndrome, 763

non-Hodgkin's lymphoma, ... 763
RHCE genotyping
blood group typing, ... 852
polymerase chain reaction, ... 852
immunohematology, ... 852
RHD genotyping
blood group typing, ... 852
polymerase chain reaction, ... 852
immunohematology, ... 852
RHD-CE-D gene, genetic origin, ... 1259
Rh-negative blood donor, ... 1128
Ricinus communis agglutinin I
NOR polyagglutination, ... 32
St^a glycophorin, ... 32
Rocky Mountain spotted fever, ... 828
S
S-59
febrile nonhemolytic transfusion reaction, ... 239
interleukin ... 8, 239
Sanofi-Pasteur Scangel
antibody reactivity, ... 1045
anti-Le^a antibody, ... 1045
anti-Le^b antibody, ... 1045
anti-M antibody, ... 1045
anti-N antibody, ... 1045
anti-P_1 antibody, ... 1045
tube low-ionic-strength solution indirect antiglobulin test, compared, ... 1045
Screening
HLA sensitization, ... 103
syphilis, ... 206
Second-generation particle agglutination test, ... 1104
Second-messenger effector, platelet concentrate, quality assessment, ... 135
Semiautomated solid-phase method of screening, red cell antibody, ... 26
Sensitivity, AmpliScreen Hepatitis C (HCV) Test, ... 1111
Sensitivity analysis
pooled random-donor platelet, ... 925
single-donor platelet, ... 925
Sepacell filter, temperature, ... 265
Sepsis, ... 179
Septic arthritis, allogeneic blood transfusion, ... 694
Seroconversion, human T-cell lymphotropic virus type I, ... 1104
adult T-cell lymphoma, ... 1104
enzyme-linked immunosorbent assay, ... 1104
human T-cell lymphotropic virus type I associated myelopathy, ... 1104
immunoblotting, ... 1104
immunofluorescence assay, ... 1104
nested polymerase chain reaction, ... 1104
second-generation particle agglutination test, ... 1104
uveitis, ... 1104
Serologic reagent, ... 364
Severe combined immune-deficient mice, ... 818
Severe combined immunodeficiency, ... 343
Sexually transmitted virus
GB virus type C/hepatitis G virus anti-E2, ... 83
GB virus type C/hepatitis G virus RNA, ... 83
high risk, ... 83
low risk, ... 83
SH
Denmark, ... 593
FcγRIIIB polymorphism, ... 593
polymerase chain reaction with sequence-specific primers, ... 593
Short tandem repeat analysis, ... 1247
Short-term culture, dextran sedimentation, ... 1212
Sickle cell disease, ... 873
Simulation model, human immunodeficiency virus type 1, ... 1141
Sindbis virus
ethanol precipitation, ... 249
pasteurization, ... 249
Single-donor platelet
acquisition cost differential, ... 925
acute myelogenous leukemia, ... 925
administration, ... 925
automated collection system, ... 460
breast cancer, ... 925
chronic myelogenous leukemia, ... 925
coronary artery bypass grafting, ... 925
cost-effectiveness, ... 925
decision analysis model, ... 925
hemotopoietic progenitor cell transplantation, ... 925
hepatitis B virus, ... 925
hepatitis C virus, ... 925
human immunodeficiency virus, ... 925
human T-cell lymphotropic virus type I, ... 925
human T-cell lymphotropic virus type I-associated myelopathy, ... 925
leukemia, ... 925
non-Hodgkin's lymphoma, ... 925
sensitivity analysis, ... 925
Sodium citrate, ... 1266
Sodium nitroprusside, platelet activation, ... 506
Soluble vascular endothelial growth factor
blood components, ... 1078
buffy coat-depleted saline-adenine-glucose-mannitol blood, ... 1078
buffy coat-derived platelet pool, ... 1078
enzyme-linked immunosorbent assay, ... 1078
platelet-rich plasma, ... 1078
storage, ... 1078
white cell-reduced whole blood, ... 1078
Solvent/detergent-treated fresh-frozen plasma
coagulation factor, ... 1150(L)
Creutzfeldt-Jakob disease, ... 107(L)
factor VIII, ... 1227
liver disease coagulopathy, ... 1227
liver transplantation, ... 1227
clotting factor, ... 1227
hepatitis A virus, ... 1227
hepatitis B virus, ... 1227
hepatitis C virus, ... 1227
human immunodeficiency virus, ... 1227
human parvovirus B19, ... 1227
partial thromboplastin time, ... 1227
transfusion practice, ... 1227
Sophora japonica lectin, *Aplysia* gonad lectin, ... 1060
Southern blot analysis, *RH* gene, ... 1259
Spectra apheresis, ... 1200
dendritic cell, ... 661(L)
mononuclear cell, ... 661(L)
Spectra Leukocyte-Reduction System
thrombocytopenia, ... 960
white cell-reduced apheresis platelet, ... 960
Spectra LRS separator
AMICUS separator, efficiency compared, ... 895
donor reactions, ... 895
platelet, ... 895
white cell-reduced component, ... 895
St^a glycophorin
glycolipid, ... 32
glycophorin, ... 32
Griffonia simplicifolia IB4 lectin, ... 32
immunohematology, ... 32
Ricinus communis agglutinin I, ... 32
Staphylococcal protein A immunoadsorption system
acetylcholine receptor, ... 682
autoimmune disorder, ... 682
IgG antibody, ... 682
myasthenia gravis, ... 682
Stem cell factor, ... 899
Storage
antibody reactivity, ... 1272(L)
biologic response modifier, ... 498

blood component, ... 951, 991
CD41, ... 74
CD42b, ... 74
CD62p-positive platelet, ... 74
CD63-positive platelet, ... 74
clotting factor, 8 *vs.* 24 hours, ... 488
cytokine, ... 239
fibrinogen binding, ... 74
fresh-frozen plasma, i *vs.* 24 hours, ... 488
granulocyte, ... 983
hematopoietic progenitor cell
  5- vs 10-percent dimethyl sulfoxide, ... 70
  burst-forming units–erythroid, ... 70
  colony-forming units–granulocyte-macrophage, ... 70
  lengths of storage time, ... 70
  mononuclear cell, ... 70
lactate, ... 492
platelet activation, ... 498
  platelet membrane integrity, ... 616
platelet antigen, ... 742
platelet component, ... 498
platelet concentrate, ... 135
  activation-dependent antigens, ... 951
  platelet adhesive and cohesive functions, ... 951
  procoagulant activity, ... 951
  sterility testing false-positive and false-negative results, ... 539(L)
platelet storage lesion, ... 258
RANTES, ... 498
red cell, ... 128
  dextran-containing buffer, ... 277
  immunomodulation, ... 701
  postoperative pneumonia, ... 701
  red cell aggregability, ... 277
  red cell alteration, ... 277
red cell 2,3 DPG, ... 492
soluble vascular endothelial growth factor, ... 1078
temperature
  5- vs 10-percent dimethyl sulfoxide, ... 70
  lengths of storage time, ... 70
ThromboSol, ... 135
transforming growth factor-β, ... 498
white cell reduction, ... 724
whole blood
  bicarbonate, ... 492
  blood gases, ... 492
  glucose, ... 492
  lactate, ... 492
  pH, ... 492
  red cell 2,3 DPG, ... 492
^{125}I-Streptavidin, ... 149
Sub-Saharan African, CD36 deficiency, ... 873
Subtype 1a, hepatitis C virus, ... 1194
Sucrose, platelet, ... 616
Suppressor T cell
  buffy coat-depleted red cell, ... 1089
  white cell filtered red cell, ... 1089
Surgical bleeding, activated partial thromboplastin time, ... 56
  sensitivity of tests compared, ... 56
Sweden
  human T-lymphotropic virus type II immunoassay, ... 845
    sensitivity, ... 845
    specificity, ... 845
  maternal health care program, ... 26
Swine model
  Adsol blood preservative, ... 998
  CPDA-1 blood preservative, ... 998
Syphilis, ... 473
  automated specific treponemal test, ... 206
  fluorescent treponemal antibody absorption test, ... 206
  rapid plasma reagin test, ... 206
  screening, ... 206
Systolic blood pressure, therapeutic apheresis, ... 282

T
T cell, ... 818
  buffy coat-depleted red cell, ... 1089
  white cell filtered red cell, ... 1089
Tartrate-resistant acid phosphatase, ... 410
tax gene, ... 795(E)
Tc(a+) red cell
  anti-Tc^a, ... 948
  Cromer system antibody, ... 948
T-cell proliferation
  allogeneic white-cell reduced blood, ... 1089
  autologous white-cell reduced blood, ... 1089
  buffy coat-depleted red cell, ... 1089
  white cell filtered red cell, ... 1089
T-cell-mediated immunity, orthopedic surgery, ... 1089
Temperature
  antibody screening, 37°C agglutinins, ... 229(E)
  Aplysia gonad lectin, ... 1060
  blood component, ... 991
  BPF4 filter, ... 265
  Cellselect FR filter, ... 265
  Cellselect Optima Plus filter, ... 265
  clotting factor, ... 488
  fresh-frozen plasma, ... 488
  hematopoietic progenitor cell
    burst-forming units–erythroid, ... 70
    colony-forming units–granulocyte-macrophage, ... 70
    mononuclear cell, ... 70
  Imugard filter, ... 265
  lactate, ... 492
  Leucoflex filter, ... 265
  platelet activation, platelet membrane integrity, ... 616
  red cell 2,3 DPG, ... 492
  Sepacell filter, ... 265
  storage
    5- vs 10-percent dimethyl sulfoxide, ... 70
    lengths of storage time, ... 70
  whole blood
    bicarbonate, ... 492
    blood gases, ... 492
    glucose, ... 492
    lactate, ... 492
    pH, ... 492
    red cell 2,3 DPG, ... 492
Thai population
  C302T mutation, ... 1013
  α (1,2)-fucosyltransferase gene mutation, ... 1013
  Le(a+b+), ... 1013
  Le(a+b–), ... 1013
Thalassemic patient
  hepatitis G virus, ... 336(L)
  hepatitis GB virus type C, ... 336(L)
  lipid peroxidation product, ... 333(L)
Therapeutic apheresis
  chills, ... 282
  citrate, ... 282
  diaphoresis, ... 282
  incidence of adverse effects, ... 282
  nausea, ... 282
  respiratory distress, ... 282
  systolic blood pressure, ... 282
  transfusion reaction, ... 282
  vasovagal nausea, ... 282
  vasovagal phenomenon, ... 282
Therapeutic monoclonal anti-D, ... 1005
Therapeutic phlebotomy
  blood usage, ... 549, 551
  hemochromatosis
    amount of blood withdrawn, ... 651
    charges, ... 651
    insurance coverage, ... 651
    patterns, ... 651

phlebotomy site, 651
rates of withdrawal, 651
time since diagnosis, 651
hemochromatosis proband, 578
iron, 651
Third-generation enzyme immunoassay, hepatitis C virus, 335(L)
Third-generation recombinant immunoblot assay, hepatitis C virus, 335(L)
Thrombin
lipopolysaccharide, 975
monocyte, 975
tissue factor, 975
tissue factor pathway inhibitor, 975
white cell reduction, 724
Thrombocytopenia, 372
rabbit kidney injury model, blood loss reduction by infusion of human platelets, 967
Spectra Leukocyte-Reduction System, 960
β-Thromboglobulin, citrate, 1266
Thrombopoietic growth factor, 258
Thrombopoietin. *See* Mpl ligand
Thrombosis, platelet, 967
ThromboSol
platelet concentrate, 135
storage, 135
Thromboxane B_2, 135
Tick-borne pathogen, transfusion complication, 828
Tietz Textbook of Clinical Chemistry, book review, 794
Tissue factor
blood component, 975
elutriation, 975
lipopolysaccharide, 975
thrombin, 975
Tissue factor pathway inhibitor
blood component, 975
elutriation, 975
lipopolysaccharide, 975
thrombin, 975
Tissue-type plasminogen activator, citrate, 1266
Transforming growth factor-β, 144
blood component, 498
filtration, 498
gamma radiation, 498
Japan, 498
storage, 498
Transfusion
alternatives to, 1027
coronary artery bypass graft, 1070
hemoglobin, 1070
impediments to innovation, 1027
tick-borne pathogen, 828
transmittal of disease-producing gene, 795(E)
Transfusion complication
acute retroviral syndrome, 383
anti-At^a, 834
antibody detection system, 1097
anti-Tc^a, 948
bacterial infection, 694
bradykinin, 1084
buffy coat-depleted blood component, 625
buffy coat-depleted red cell, 1089
Chagas' disease, 711
chronic myelogenous leukemia donor blood, 387
cytomegalovirus, 201
delayed hemolytic transfusion reaction, 1097
delayed serologic transfusion reaction, 1097
des-Arg^9-bradykinin metabolism, 1084
GB virus type C, 212
GB virus type C/hepatitis G virus anti-E2, 83, 95
GB virus type C/hepatitis G virus RNA, 83, 95
hepatitis B virus, 1111
hepatitis C virus, 188, 194, 1111
genotypes, 1194
hepatitis C virus RNA, 1111
HGV, 633
human immunodeficiency virus, 688
human immunodeficiency virus type 1, 1111
human T-cell lymphotropic virus type I, 639, 1104, 1185
human T-cell lymphotropic virus type II, 1185
human T-lymphotropic virus type I immunoassay, 845
human T-lymphotropic virus type II immunoassay, 845
hypotensive reaction, 1084
immune hemolytic anemia, 838
platelet reaction, 231
pneumonia, 701
red cell storage, 701
syphilis test, 206
tick-borne pathogen, 828
transfusion-related acute lung injury, 944
transmissible spongiform encephalopathy, 1169
TT virus, 522
white cell filtered red cell, 1089
white cell-poor platelet preparation, 1179
Transfusion medicine, 17
future, 917(E)
in philately, 534
Transfusion Medicine, book review, 338
Transfusion Medicine Academic Award Program, 1031
Transfusion medicine specialist, 1027
credentials, 1031
defined, 1031
functions, 1031
Transfusion practice
Adsol blood preservative, 998
CPDA-1 blood preservative, 998
erythropoietin, 392
fetal immunoglobulin, 1235
fresh-frozen plasma, 1227
hydroxyethyl starch, 289
oxygen carriers, 396
platelet response, 586
platelet transfusion dose alterations, 674
solvent/detergent-treated fresh-frozen plasma, 1227
staphylococcal protein A immunoadsorption system, 682
therapeutic apheresis, 282
Transfusion rate
educational intervention, 801
hysterectomy, 801
Transfusion reaction
changing incidence of delayed, 1097
indirect antiglobulin crossmatch, 295
Jk^a antibody, 1097
polyethylene glycol technique, 1097
pretransfusion direct antiglobulin test, 295
therapeutic apheresis, 282
white cell, 1179
Transfusion Therapy: Clinical Principles and Practice, book review, 548
Transfusion trigger, 1027
Transfusion-related acute lung injury
HLA sensitization, 103
pathogenesis, 944
pregnancy, 103
white cell antibody, 944
Transmissible spongiform encephalopathy
blood component, 1169
high-speed centrifugation, 1169
infectivity levels, 1169
intracerebral route, 1169
white cell-reduction filtration, 1169
blood infectivity, 1169
plasma fraction, 1169
high-speed centrifugation, 1169
infectivity levels, 1169
intracerebral route, 1169
intravenous route, 1169

white cell-reduction filtration, ... 1169
transfusion complication, ... 1169
Transmission route, *Trypanosoma cruzi*, ... 310
Transplantation. *See also* Specific type
ABO incompatibility, ... 179
ABO-incompatible bone marrow, ... 1273(L)
allogeneic peripheral blood progenitor cell transplantation, ... 824
apheresis timing, ... 442
automated leukapheresis system, ... 1200
CD34+ cell
improved collection, ... 48
semi-automated flow cytometric analysis, ... 1220
CD40L, ... 818
dextran sedimentation, ... 1212
granulocyte–colony-stimulating factor, ... 451
growth factor dosing, ... 39
IgA deficiency, ... 457
minor ABO incompatibility, ... 824
Trehalose, platelet, ... 616
Triglyceride, AmpliScreen Hepatitis C (HCV) Test, ... 1111
Tropical spastic paraparesis, ... 1104, 1185
Trypanosoma cruzi, ... 711
blood donor
congenital transmission, ... 310
seroprevalence, ... 310
transmission route, ... 310
TT virus, ... 1041
absence of intrauterine transmission, ... 1035(L)
non-A to -G hepatitis, ... 522
polymerize chain reaction, ... 522
Tube agglutination
B isohemagglutinin, ... 300
gel agglutination assay, ... 300
weak A, ... 300
weak B, ... 300
weak D, ... 300
Tube low-ionic-strength solution indirect antiglobulin test
affinity-adherence test system, compared, ... 1045
DiaMed-ID, compared, ... 1045
Gamma ReACT, compared, ... 1045
microtube column agglutination system, compared, ... 1045
Ortho BioVue, compared, ... 1045
Sanofi-Pasteur Scangel, compared, ... 1045
Tumor cell
5-bromodesoxyuridine, ... 608
gamma radiation, ... 608
survival curves, ... 608
intraoperative blood salvage, ... 608
irradiation, ... 608
Tumor necrosis factor α, nonhemolytic transfusion reaction, ... 1179
Two-unit red cell apheresis, ... 218
advantages, ... 218
anemia, ... 218
Food and Drug Administration guidelines, ... 218
hematocrit, ... 218
iron-deficiency anemia, ... 218
red cell, ... 218
symptoms, ... 218
Type-specific Western blot assay
human T-cell lymphotropic virus type I
sensitivity, ... 1185
specificity, ... 1185
human T-cell lymphotropic virus type II
sensitivity, ... 1185
specificity, ... 1185

U

Ultraviolet A light
febrile nonhemolytic transfusion reaction, ... 239
interleukin ... 8, 239
Ultraviolet and visible light spectrophotometry
agglutination index, ... 1051
blood group, ... 1051
blood typing, ... 1051
immunohematology, ... 1051
Umbilical endothelial cell, hydroxyethyl starch, ... 289
United States, blood component recall, ... 473
frequency, ... 473
hazard class, ... 473
nature, ... 473
recall reason, ... 473
Unstable angina, granulocyte–colony-stimulating factor, ... 542(L)
Uveitis, ... 1104

V

Vaccinia virus
ethanol precipitation, ... 249
pasteurization, ... 249
Vasovagal reaction
blood donor, ... 316
age, ... 316
blood pressure, ... 316
donation status, ... 316
pulse, ... 316
sex, ... 316
weight, ... 316
therapeutic apheresis, ... 282
Very-low-birthweight infant, limited-donor program, ... 938
Vesicular stomatitis virus
ethanol precipitation, ... 249
pasteurization, ... 249
Viral nucleic acid, testing, ... 1111
Virus, nomenclature, ... 1041
Virus inactivation, ... 1027
Virus transmission
albumin, ... 1160
antihemophilic factor, ... 1160
factor IX complex, ... 1160
GB virus type C/hepatitis G virus anti-E2, ... 83
GB virus type C/hepatitis G virus RNA, ... 83
immune globulin product, ... 1160
plasma derivative, ... 1160
Virus-inactivated cellular concentrate, ... 1027
Virus-inactivated plasma, ... 1027
cost-effectiveness, ... 479
hepatitis B virus, ... 479
hepatitis C virus, ... 479
human immunodeficiency virus, ... 479
Volumetric capillary cytometry
apheresis component, ... 864
CD34+ cell, ... 864
cord blood, ... 864
flow cytometry, compared, ... 864
immunohematology, ... 864
peripheral blood, ... 864
von Willebrand disease, methylene blue, ... 748
von Willebrand factor, ... 135
platelet concentrate preparation, ... 951

W

Warm autoantibody, alloantibody
1-in-5 dilution approach, ... 11
detection methods compared, ... 11
dithiothreitol and enzyme reagent, ... 11
polyethylene glycol adsorption, ... 11
ZZAP adsorption, ... 11
Washed red cell
cytokine, ... 271
hemoglobin, ... 271
Weak A
gel agglutination assay, ... 300
tube agglutination, ... 300
Weak B
gel agglutination assay, ... 300
tube agglutination, ... 300

Weak D
gel agglutination assay, ... 300
tube agglutination, ... 300
Weight, blood donor, ... 316
West Africa, human T-lymphotropic virus type II immunoassay, ... 845
sensitivity, ... 845
specificity, ... 845
Western blot assay
acute retroviral syndrome, ... 383
AIDS, ... 383
human T-cell lymphotropic virus type I
indeterminate, ... 1145
sensitivity, ... 1185
specificity, ... 1185
human T-cell lymphotropic virus type II
sensitivity, ... 1185
specificity, ... 1185
immunosilent AIDS, ... 383
White cell
aluminum phthalocyanine tetrasulfonate, ... 599
annexin V, ... 599
apheresis
cell count predictive value, ... 442
maximizing yield, ... 442
apoptosis induction, ... 599
CD34+ cell, ... 403
cytomegalovirus
endemic area, ... 201
filtered-irradiated blood, ... 201
newborn infant, ... 201
nonfiltered-irradiated blood, ... 201
hydroxyethyl starch, ... 289
phthalocyanine, ... 599
polymorphonuclear cell, ... 403
transfusion reaction, ... 1179
White cell antibody, transfusion-related acute lung injury, ... 944
White cell reduction
activation marker expression, ... 724
AMICUS device, ... 572
apheresis platelet, ... 74
AS.TEC ... 204, 572
CD62, ... 724
CD63, ... 724
cell separator, compared, ... 572
complement activation, ... 724
Creutzfeldt-Jakob disease, ... 107(L)
cytokine, ... 718
cytomegalovirus, ... 201
fibrinolysis, ... 724
hypotonic shock response, ... 724
immunomodulation, ... 665(E)
in-line filter system, ... 572, 960
in-line filtration, ... 572
interferon gamma, ... 718
interleukin-2, ... 718
limited-donor program, ... 938
lymphocyte, ... 718
lymphopenia, ... 718
MCS+, ... 572
MCS+ LN9000 apheresis system, continuous filtration, ... 74
natural killer cell, ... 718
new variant Creutzfeldt-Jacob disease, ... 919(E)
orthopedic surgery, ... 718
pH, ... 724
plasma enzyme system, ... 724
platelet activation, ... 724
platelet aggregate, ... 724
platelet concentrate, ... 724
plateletpheresis, cell separators compared, ... 572
postcollection filtration, ... 74
bedside filtration, ... 74
prestorage, ... 107(L), 1179
prestorage inline filtration, ... 107(L)
storage, ... 724
thrombin, ... 724
white cell filtering temperature, ... 265
White cell reduction filter, ... 74
White cell-derived inflammatory cytokine, nonhemolytic transfusion reaction, ... 1179
White cell-reduced apheresis platelet
blood component, ... 960
COBE Spectra, ... 960
fluidized particle-bed separation, ... 960
in-line white cell-reduction system, ... 960
Spectra Leukocyte-Reduction System, ... 960
White cell-reduced blood component, ... 1027
AMICUS separator, ... 895
Spectra LRS separator, ... 895
White cell-reduced platelet component
allergic transfusion reaction, ... 1179
automated collection system, ... 460
bedside filtration, ... 1179
febrile transfusion reaction, ... 1179
prestorage white cell filtration, ... 1179
transfusion complication, ... 1179
White cell-reduced red cell
helper T cell, ... 1089
mixed lymphocyte culture, ... 1089
phytohemagglutinin, ... 1089
suppressor T cell, ... 1089
T-cell proliferation, ... 1089
T-lymphocyte, ... 1089
transfusion complication, ... 1089
White cell-reduced whole blood, soluble vascular endothelial growth factor, ... 1078
White European patient, CD36, ... 873
Whole blood
filtered
cytokine, ... 271
hemoglobin, ... 271
storage
bicarbonate, ... 492
blood gases, ... 492
glucose, ... 492
lactate, ... 492
pH, ... 492
red cell 2,3 DPG, ... 492
temperature
bicarbonate, ... 492
blood gases, ... 492
glucose, ... 492
lactate, ... 492
pH, ... 492
red cell 2,3 DPG, ... 492
Wound healing, ... 144
Wound infection, allogeneic blood transfusion, ... 694
Z
ZZAP adsorption, ... 11